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For last many years, clinical, research and industrial advancements are hampered due 
to the limited availability and huge variation of primary cell sources. However, 
human embryonic stem cells (hESCs) have been proposed recently as an alternative, 
unlimited and human in origin cell source which can be used to obtain specialized 
cells. However, the application of hESCs in dentistry is new and has not been 
addressed in detail. Therefore, in this study, I not only addressed the potential of 
hESCs as a cell source but also addressed the clinical, research and industrial 
application of hESC-derived specialized cells i.e. keratinocytes. My overall results 
support the potential of human embryonic stem cell-derived keratinocytes (hESCs-
Kert) for future clinical application to treat patients. Moreover, expression of relevant 
toll like receptors (TLRs) and cytokines in physiological and pathological condition 
by hESCs-Kert also authenticate their potential use as a research model for the study 
of host-pathogen interactions and disease pathogenesis.  Furthermore, I found that 
hESCs-Kert were able to form a multi-layer epithelium (MLE). An ideal MLE model 
plays an important role in the success of new therapeutic modalities by providing an 
in vitro model for understanding of disease pathogenesis, evaluating drug treatment 
and delivery mechanisms. Investments to establish such an MLE model is estimated 
at $100 million per annum in United States. My results support the application of 
hESCs derived MLE (hESCs-MLE) model for industrial application due to their 
appropriate barrier properties. In the future, I would like to examine drug delivery and 
early pathological events in cutaneous and mucosal tissues, including microbial 
invasion and colonization. Moreover, the hESCs-MLE model will also increase our 
understanding of skin repair and regeneration, maintenance process and wound 
healing therapies in a defined environment. This will also reduce our reliance on live 
animals and human volunteers for scientific experimentation. 
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Human body comprises of several   specialized cells. These specialized cells in the 
body have different functions but they all 'stem' from simpler undifferentiated cells. 
These undifferentiated cells are known as ‘stem cells’ (SCs). The precise definition of 
SCs has not been reported due to limitations in their isolation and in their inherent 
biological differences depending on their origins. However, it is generally accepted 
that the SCs have the ability to undergo unlimited self-renewal for indefinite period of 
time. Furthermore, under  appropriate conditions and  signals, SCs can give rise to 
differentiated cells with specialized functions and characteristic morphologies e.g. 
heart cells, skin cells, nerve cells, and others (Lajtha 1979, Tudor et al. 2004, Odorico 
et al. 2001, Reya et al. 2001)  Concurrently, according to National Institute of Health 
resources of Stem Cells Research,  SCs  may have the following properties:  
• They have the capacity for self-renewal  
• They are undifferentiated 
• Under certain physiological and experimental conditions they can give rise to 
cells that can differentiate into specialized cells of different organs.  
1.1  Classification of SCs based on the plasticity potential 
 
Based on the developmental plasticity, SCs may have the following plasticity 
potentials: totipotency, pluripotency, multipotency, oligopotency, and unipotency. 
I. Totipotency: The word ‘toti’ is derived originally from Latin word ‘tōtus’ 
that means ‘entire’. Word ‘potent’ is derived from Latin word ‘potēns’ that means ‘to 
have power’. Totipotent SCs can differentiate into all cell lineages including the 
trophoblast and the germ line (Polak & Hench 2005). Example of totipotent SCs is 
zygote; the resulting cell after sperm fertilizes an egg. Zygote can give rise to all the 
cells and tissues of a developing embryo (Lemoli et al. 2005).  
II. Pluripotency: The word pluripotent comes from the Latin word plurimus, 
meaning ‘very or many’, and potent, means ‘to have power’. Pluripotent SCs are 
descendants of totipotent SCs and are able to differentiating into cells originating 
from three germ layers viz. ectoderm (neurons, skin, etc.), mesoderm (muscle, bone, 
etc.) and endoderm (hepatocytes, pancreatic beta cells, etc.)  (Thomson et al. 1998). 
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In theory, pluripotent SCs have the ability to form around 200 or more cell types 
present in the body. Example of pluripotent SCs is human embryonic stem cells 
(hESCs) which can be derived from the inner cell mass (ICM) of the blastocyst and 
can differentiate into any cell type originating from the three germ layers (Smith 
2001).  
(i)  Induced pluripotent SCs: Induced pluripotent SCs are the 
type of pluripotent SCs that are derived from genetically 
altered somatic cells. Although induced pluripotent SCs are 
like embryonic SCs, they are not exact duplicates of 
embryonic SCs in terms of their pluripotent gene expression. 
 
III. Multipotency: Multipotent SCs are capable of undergoing self-renewal, and 
have the potential to give rise to cells within a defined spectrum of specialization i.e. 
cells of only one germ layer (ectoderm, mesoderm or endoderm) (Polak & Hench 
2005). Moreover, the ability of most tissues of adult organisms (e.g. bone, skin, 
haematopoietic system, liver etc.) to repair or to renew indicates the persistence of 
multipotent SCs throughout life (Vats et al. 2005). Also known as ‘adult SCs’, the 
functional role of these multipotent SCs is repairing and renewing, depending upon 
their presence in a  special zones within  tissues and organs (niches) which appear to 
have special properties that support  multipotent SCs  survival (Spradling et al. 2001, 
Watt & Hogan 2000). Mesenchymal SCs from tooth (dental mesenchymal SCs) is 
one of the examples of multipotent SCs.  Dental mesenchymal SCs can give rise to 
different types of tooth forming cells (Ohgushi et al. 2011). 
 
IV. Oligopotency: Oligopotency is an ability of progenitor cells. Oligopotent 
progenitors can give rise to few cell types of defined germ layer.  Vascular SCs is one 
of the examples which can give rise to endothelial and smooth muscles cells 
(National Institute of Health resources of Stem Cells Research).  
V.  Unipotency: Unipotent SCs possess the capacity of self-renewal. However 
these SCs can give rise to only one cell type or tissue. Epidermal SCs are one of the 
examples of unipotent SCs which readily undergo cell division to replace damaged 
cells (National Institute of Health resources of Stem Cells Research). 
Classification of SCs depending on the basis of developmental plasticity is 
summarized in Table 1 below 
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Table 1 : Characterization of SCs based on the plasticity potential 
 
Stem Cells Categories Plasticity 
property 
Example 
Totipotent SCs Give rise to every 





 Give rise to all 
cells derived from  








Multipotent SCs Give rise to types 
of cells derived 




Oligopotent SCs Give rise to few 
cells of one germ 
layer 
Vascular SCs 
Unipotent SCs Give rise to one 




Reference: National Institute of Health resources of Stem Cells Research 
 
 
1.2 Classification of SCs based on their derivation sources 
 
In addition to plasticity potential, SCs can also be classified into six categories based 
on their derivation sources: Embryonic SCs, Embryonic germ SCs, Fetal SCs, 
Epiblast SCs, Umbilical cord SCs, and Adult SCs (Bongso & Lee 2010).  
I.  Human Embryonic SCs (hESCs):  hESCs are derived from inner cell mass 
of blastocyst before implantation in the uterus. Furthermore, hESCs are pluripotent in 
nature i.e. they can differentiate into any cell type originating from three germ layers. 
Nevertheless, hESCs are capable of growing and proliferate unlimited time and 
should form a teratoma after their injection into immunocompromised mice 
(Thomson et al. 1998).  
 
II. Human Embryonic Germ SCs:  Embryonic Germ SCs are derived from 
Gonadal ridge i.e. early fetal tissue (Resnick et al. 1992). Moreover, Embryonic 
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Germ SCs are also pluripotent by nature and can give rise to cells of all the three 
germ layers. However, unlike hESCs, Embryonic Germ SCs are not immortalized by 
nature and have limited range of expansion and proliferation (Resnick et al. 1992).  
 
III. Fetal SCs: Fetal SCs are derived from abortus fetal organs. Although, Fetal 
SCs are multipotent in nature and highly proliferative. However, they are not 
immortalized by nature (Bongso & Lee 2010).  
 
IV.  Epiblast SCs: Similar to hESCs, Epiblast SCs are pluripotent in nature and 
can give rise to cells derived from all three germ layers. However, Epiblast SCs are 
derived from columnar cells of epiblast blastocyst and more prone to differentiate 
into ectoderm. (Tesar et al. 2007).   
 
V. Umbilical cord SCs: Umblical cord SCs are multipotent in nature, but 
exhibit a stronger tendency to differentiate towards the mesenchymal lineages (Flynn 
et al. 2007). Based on their derivation, Umblical cord SCs are further divided into 
(i) Umblical cord blood SCs: Umblical cord blood SCs are 
derived from umblical cord blood 
(ii)  Umblical cord matrix SCs: Umblical cord matrix SCs are 
derived 
from Wharton’s Jelly 
 
VI. Adult SCs: Adult SCs are derived from mature tissues and/or organ. Adult 
SCs are multipotent in nature.  Although Adult SCs can undergo self-renewal, they 
have limited growth and proliferative properties (Ratajczak et al. 2007). 
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Table 2: Characterization of SCs based on their derivation sources 
Stem Cells Categories Source Properties 




Human Embryonic Germ SCs Gonadal Ridge Limited 
proliferation. 
Pluripotent 
Fetal SCs Abortus fetal tissue Limited 
proliferation. 
Multipotent 



















Adult SCs Mature tissue/organ Limited proliferation 
Multipotent 
 
Above-mentioned SCs have their own specific advantages and properties. However, 
hESCs are found to be more advantageous than other types of SCs in two main 
aspects: 
(i) hESCs are immortalized in nature. Therefore they can 
propagate in vitro in an unlimited fashion. They are of human origin 
and provide a consistent, reliable and limitless cell source.  
(ii) hESCs can differentiate into all type of cells of the body. 
Therefore, they can be used as an potential source for generation and 
differentiation of broader types of cells. 
 
1.3 Human Embryonic Stem Cells 
 
The first Embryonic Stem cells (ESCs) were isolated from the ICM of early mouse 
embryos in the University of California to distinguish these pluripotent ESCs from 
teratocarcinoma-derived pluripotent embryonal carcinoma cells based on the 
following characteristics (Evans & Kaufman 1981): 
 1) Derived from preimplantation and periimplantation embryo. 
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 2) Potential to proliferate in an undifferentiated state for prolonged period. 
 3) Potential to differentiate into all three embryonic germ layers  
However, first human ESCs (hESCs)  isolation was reported by Thomson JA in 1998 
(Thomson et al. 1998). Since then hESCs research has progressed at a spectacular 
pace due to their capacity to propagate and proliferate in an undifferentiated state for 
prolonged period of time. Concurrently, due to the pluripotent property of hESCs, 
they can differentiate into any cell type with potential therapeutic, research and 
industrial use. To date, there are around 200 hESCs cell lines are available to 
National Institutes of Health (NIH) supported researchers derived by over 70 
investigators (Amit & Itskovitz-Eldor 2002, Reubinoff et al. 2000, Richards et al. 
2002, Strelchenko et al. 2004, Stojkovic et al. 2004). Moreover, there are 182 eligible 
hESCs lines registered in National Institutes of Health (NIH) Human Embryonic 
Stem Cell Registry.  However, 3 hESCs cell lines out of 182 cell lines are on hold as 
NIH is considering some public comments on a proposed change in the definition of 
hESCs in NIH Guidelines for hESCs research (National Institute of Health office of 
Extramural Research). 
1.3.1 Characterization of hESCs 
 
hESCs are derived from ICM of blastocysts. ICM contains all the cells which can 
give rise to embryo itself. It is interesting to know that the ICM in an embryo 
undergoes differentiation and loses its pluripotency in a short time. However, in an 
optimized culture milieu ICM gives rise to hESCs with two main core properties 
namely self-renewal and pluripotency (Nishikawa et al. 2007).  
 
1.3.1.1 Self-renewal of hESCs 
 
Self-renewal is defined as the capability of a cell to undergo cell division without 
change. Previously, it has been reported that self- renewal of hESCs is regulated by 
FGF, transforming growth factor-β (TGF-β)/Activin and Bone Morphogenetic 
Proteins (BMPs) pathway (Levenstein et al. 2006, Dvorak & Hampl 2005, James et 
al. 2005, Xiao et al. 2006).   Moreover, FGF family through FGF-2 gene plays a vital 
role in keeping the hESCs at the self-renewal state (Amit et al. 2000, Levenstein et al. 
2006). FGF-2 gene is encoded by four isoforms high molecular mass of ((HMM) of 
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22 kDa, 22.5 kDa, 24 kDa, and 34 kDa) and one low molecular mass ((LMM) of 18-
KDa) (Arnaud et al. 1999, Dvorak et al. 2006). Previously, the elevated level of FGF-
2 in activation and phosphorylation in downstream signaling in undifferentiated 
hESCs have been reported by several groups (Wei et al. 2005, Dvorak et al. 2005, 
Ginis et al. 2004, Rao & Stice 2004). Concurrently, the role of TGF-β/Activin 
signaling in regulating the self-renewal of hESCs is well-established (Besser 2004, 
James et al. 2005, Wang et al. 2005). Additionally, the cross talk between TGF-
β/Activin and FGF signalling has also been reported (Vallier et al. 2005). 
Alternatively, previous studies have also demonstrated that the suppression of TGF-
β/BMPs/SMAD5 signaling pathway is required for keeping the stemness of hESCs 
(Greber et al. 2007).  
To date,  the self-renewal of hESCs has been analysed with the expression of the 
surface markers like stage-specific embryonic antigen   (SSAE) – 3, SSAE – 4 , 
Alkaline Phosphatase (ALP), Terato- related antigen (TRA) 1- 60 (Rosler et al. 2004, 
Venable et al. 2005); and transcription factors Nanog (Chambers et al. 2003) , sox2 
(Avilion et al. 2003), and Oct4 (Nichols et al. 1998). The following section will 
discuss the role of above-mentioned transcription factors individually  
Stage-specific embryonic antigen 3 and 4 (SSEA 3 and SSEA 4): SSEA is 
a glycosphingolipid composed of five carbohydrate units connected to a sphingolipid. 
It plays a key role in identifying many types of mammalian cells 
with pluripotent and stem cell-like characteristics (Kannagi et al. 1983). hESCs 
express SSEA-3 and SSEA-4 (Thomson et al. 1998). The globo-series glycolipid 
GL7, which carries the SSEA-4 epitope, is formed by the addition of sialic acid to the 
globoseries glycolipid Gb5, which carries the SSEA-3 epitope (Kannagi et al. 1983). 
Moreover, SSEA-3 and SSEA-4 determinants are associated with a variety of cell 
surface glycopeptides (Shevinsky et al. 1982)  
Alkaline Phosphatase (ALP):  ALP is homodimeric enzyme in which each catalytic 
site contains three metal ions, i.e., two Zn and one Mg, necessary for enzymatic 
activity. The enzymes catalyse the hydrolysis of monoesters of phosphoric acid and 
also catalyse a transphosphorylation reaction in the presence of large concentrations 
of phosphate acceptors. (Millán 2006). The central core of human ALP consists of an 
extended β-sheet and flanking α-helices. Moreover, the overall structure of human 
ALP is a dimer and each monomer contains four metal atoms, 484 residues, 603 
water molecules and one phosphate ion (Le Du et al. 2001). Expression of ALP by 
undifferentiated hESCs is well established (O'Connor et al. 2008).   
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Terato- related antigen 1- 60 (TRA-1-60): The TRA-1-60 antigen is associated with a 
poly disperse glycoprotein with a molecular weight in excess of 200,000 (Andrews et 
al. 1984). Sequential immunoprecipitation experiments have suggested that the TRA-
1-60 is associated with distinct molecular species (Andrews et al. 1984). TRA-1-60 is 
stem cell marker, which is widely used in human stem cell research as positive 
indicators of a true pluripotent human stem cell (Malecki et al. 2012). Moreoever, 
TRA-1-60 epitopes is lost once the hESCs undergo differentation, therefore, the loss 
of TRA-1- 60  reactivity on the surface of the stem cell is one of the established 
properties that define stem cell differentiation (Malecki et al. 2012).  
 
1.3.1.2 Pluripotency of hESCs 
 
Pluripotency can be defined as the ability of hESCs to differentiate into derivatives of 
all three germ layers (Carpenter et al. 2003). Transcription factors (nanog, sox2 and 
Oct4) play a vital role in maintaining the pluripotency of hESCs (Boyer et al. 2005). 
The following section will discuss the role of above-mentioned transcription factors 
individually.  
Nanog is homeobox transcription factor which is required to keep hESCs in 
pluripotent state (Avery et al. 2006).  Previously it has been shown that nanog 
expression is restricted to pluripotent cells and is down-regulated in differentiated 
cells (Jaenisch & Young 2008). nanog holds close association with Oct4 and sox2 
transcription factors by regulating their synergic binding to the nanog promoter 
during the pluripotent state of the hESCs (Pan & Thomson 2007, Kuroda et al. 2005).  
Sox2 transcription factor belongs to high-mobility-group box, and, in collaboration of 
Oct4 transcription factor, is responsible to keep the pluripotency of hESCs (Facucho-
Oliveira & St John 2009). Additionally, the expression of Sox2 is controlled by the 
Oct4-sox2 complex (Tomioka et al. 2002). However, unlike nanog, sox2 expression 
is not restricted to pluripotent cells.  Previously, it has been shown that sox2 also 
express in central nervous system progenitors and ectodermal precursors, suggesting 
the potential of sox2 in developmental preservation (Fong et al. 2008).  
Oct4 belongs to homeodomain transcription factor of POU family and is associated 
with maintaining the pluripotency of hESCs (Herr et al. 1988, Pan et al. 2002). Oct4 
expression is controlled at transcription level by methylation of chromatin structure 
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and cis-acting element of Oct4 gene (Ben-Shushan et al. 1993). Additionally, 
activation of Oct4 regulates the expression of sox2 transcription factor; resulting in 
the formation of Oct4-sox2 complex as mentioned in previous section. Moreover, the 
downregulation of Oct4 promotes the differentiation of hESCs into derivatives of all 
three germ layers  (Niwa et al. 2000, Shimozaki et al. 2003, Reim et al. 2004). 
Alternatively, Oct4 expression in differentiated cells has been reported; suggesting its 
conservative role in development (Zangrossi et al. 2007).   
The pluripotency of hESCs is analysed by embryoid body (EB) and/or teratoma 
formation in vitro and in vivo respectively. EBs are the cell aggregates formed by 
hESCs in  suspension culture conditions, and express markers specific to all three 
germ layers (Itskovitz-Eldor et al. 2000). Alternatively, teratoma is formed by hESCs 
after their injection in severe combined immunodeficiency (SCID) mice. Teratoma 
consists of tissues from all three germ layers (ectoderm, mesoderm and endoderm) 
(Gschwend et al. 1987). Therefore, teratoma formation is considerned as the gold 
standard assessment of potential of hESC to differentiate into specialized cells of all 
three germ layers (Lensch et al. 2007).  
 
1.3.2 Differentiation of hESCs into specialized cells of all three germ layers 
 
 
The SCs research has been progressing at a magnificent pace since the advent of 
hESCs in 1998. The pluripotent nature of hESCs offers enormous opportunity as a 
developmental tool for comprehending the physiological and pathological process, it 
holds great promise for regenerative dentistry and medicine by offering unlimited 
supply of specialized cells (Figure 1) for therapeutic applications including retinal 
degeneration, burns, diabetes, Parkinson’s disease, osteoarthritis, spinal cord injury 
etc.  





                      Adapted from http://www.innovitaresearch.org/news/04121501.html 
Figure 1: Schematic representation of hESCs potential to differentiate into different cell types of 
all three germ layers 
 
hESCs can be differentiated into specialized cells originated from all three germ 
layers (ectoderm, mesoderm and endoderm) (Thomson et al.1998 )  and extra 
embryonic lineage (Thomson et al. 1996). Moreover, hESCs cell line transcribed 
genes for neurofilament 68kDa subunit, ζ-globin, α-cardiac and α-fetoprotein, actin 
marking primitive neuroectoderm, mesoderm, and endoderm derivatives. Therefore, 
hESCs can be used as a useful model to study developmental biology (Sharp et al. 
2010),   
Recent studies have demonstrated that  hESCs differentiating in culture are able to 
express proteins associated to  Neuron and astrocyte(Ko et al. 2007, Zhang et al. 
2001, Nat et al. 2007), Oligodendrocyte (Nistor et al. 2010), Glia (Nat et al. 2007), 
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Retinal neuron/cells (Nistor et al. 2005), Motor neuron (Wada et al.2009),  
Melanocyte (Zabierowski & Herlyn 2010), Keratinocyte (Green et al. 2003),  T cells 
(Timmermans et al. 2009), Macrophage (Anderson et al. 2006), Germ cells (Clark 
2007), Erythrocyte(Lu et al. 2010), Natural killer cells (Woll et al. 2005), 
Megakaryocyte (Klimchenko et al. 2009), Dendritic cells (Tseng et al. 2009), 
Osteoblast (Smith et al. 2010), Adipocyte (Xiong et al. 2005), Smooth muscles cells 
(Vo et al. 2010), Endothelium cells ((Levenberg et al. 2002), Chondrocyte (Toh et al. 
2010), Hepatocyte (Touboul et al. 2010), Prostate tissue (Taylor et al. 2006), Type II 
pneumocytes (Schuldiner et al. 2000), Lung alveolar epithelial type II cells (Wang et 
al.2010) and Insulin producing endocrine cells  (Cai et al.2010). From these studies it 
is clear that similar to normal embryo; hESCs follow similar critical developmental 
stages to generate specialized cells in optimized in vitro conditions.  Moreover, 
hESCs have been recognised as an authentic and valuable research model for 
studying the downstream pathway involved during the early stage of human 
development (Dinsmore et al. 1998). For example, in vitro differentiation of  hESCs 
provides a unique setting to comprend the effect of extrinsic growth factors and 
cytokine on cellular differentiation (Schuldiner et al. 2000). Moreover, gene trap 
vectors can be used in differentiating hESCs to identify new genes that are essential 
in specific tissue differentiation (Thorey et al. 1998). Thus, pathways of hESCs 
derived cell lineage can be studied using this in vitro model system. 
 
1.4 Differentiation of hESCs into keratinocyte  
 
During embryogenesis, keratinocyte differentiation initiates by the expression of K18 
(+) cells in primitive epithelium. Later on, these K18 (+) cells replace by keratinocyte 
progenitors p63 (+) cells (Shalom-Feuerstein et al. 2011). Additionally, it has been 
reported previously that expression of p63 (+) cells results in induction of genes like 
Ly6/PLAUR domain-containing 3 (LYPD3), integral membrane 2B,  lymphocyte 
antigen 6 complex (LY6G6C), RAB25 (Ras-related protein Rab-25), Nucleoside 
Diphosphate Kinase 2  (NME 2) , insulin-like growth factor-binding protein 3 
(IGFBP3), insulin-like growth factor 2 (IGF2), Wnt-related genes and  fibroblast 
growth factor receptor 2 (FGFR2), which subsequently, give rise to basal 
keratinocytes (K14 (+) and integrin alpha 6 (+)) cells of stratified epidermis (Shalom-
Feuerstein et al. 2011, Metallo et al. 2010).  hESCs-derived keratinocyte (hESCs-
Kert) hold great clinical,  research and industrial potential due to their unlimited 
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supply with minimum batch-to-batch variation. Therefore, current efforts are focusing 
on the application of hESCs-Kert for regenerative medicine and dentistry and 
development of useful in vitro model for research and industrial application. 
However, to utilize hESCs-Kert; it is vital to establish an optimized and efficient 
protocol for hESC differentiation into relatively pure population of keratinocytes and 
a suitable culture milieu for their maintenance and expansion. Thus, this section of 
the thesis covers the literature review on various strategies that have been employed 
to direct the hESCs into the keratinocyte lineage, and subsequent isolation and growth 
of hESCs-Kert.  
 
1.4.1 Strategies for derivation of hESCs-Kert 
 
Lineage-specific differentiation of hESCs is critical and holds great significance in 
hESCs research. To date, two main strategies have been employed to differentiate 
hESCs into keratinocyte: 1) Spontaneous differentiation of hESCs into keratinocyte 
lineage; 2) Application of exogenous growth factors, cytokines, chemicals and 
compounds for committing hESCs into the keratinocyte lineage. 
 
1.4.1.1 Spontaneous differentiation of hESCs into keratinocyte lineage 
 
First spontaneous keratinocyte differentiation was reported in mESCs through EBs by 
Watt’s lab in 1996 (Bagutti et al. 1996). In this study, the EBs were kept suspended 
for 3 days; followed by EBs seeded on gelatin-coated coverslips. Expression of 
keratinocyte markers were analysed at different time points. Following the similar 
concept of spontaneous differentiation, first hESC differentiation into keratinocyte 
was reported in 2003 (Green et al. 2003).  This study involved the incubation of 
hESCs in Severe Combined Immunodeficiency (SCID) mice for two months which 
resulted in the formation of    a  three germ layer structure or  ‘teratoma’  followed by 
in vitro trypsinization and cultivation of teratoma nodular cells on mitotically 
inactivated mouse 3T3 feeder cells. hESCs-Kert acquired through this strategy 
required extensive purification and selection and had limited ability to grow.  
Therefore, an attempt was made to immortalize hESCs-Kert by using E6E7 genes of 
HPV16 (Iuchi et al. 2006). However, transfected hESCs-Kert were found to have lost 
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their ability to to undergo terminal differentiation. Additionally, viral transfection 
also limited the clinical application of hESCs-Kert. 
To enhance the differentiation and efficiency of obtaining hESCs-Kert, application of 
an optimized exogenous stimulant ‘cocktail’ and use of a culture matrix substrate was 
proposed. However, the nature of the stimuli required for keratinocyte commitment 
remained unknown. Moreover, the application of non-defined cocktail of growth 
factors, cytokines and chemicals induces non-specific pleiotropic effects on hESCs 
into multiple lineages. Therefore, to optimize the keratinocyte differentiation of 
hESCs, it was pivotal to elucidate the individual and/or combined effect of different 
growth factors, cytokines, chemicals and compounds for the establishment of 
‘optimized’ culture milieu. 
 
1.4.1.2 Application of exogenous growth factors, cytokines and 
chemicals for committing hESCs to keratinocyte lineage  
 
In the process of establishing an optimized ‘cocktail’ to direct hESCs into a 
keratinocyte lineage, a ‘cocktail’ of protein based cytokines and growth factors was  
proposed. The role of these cytokines and growth factors on human primary 
keratinocyte growth and propagation were well- established and comprehensively 
reviewed by Heng et al in 2005 (Heng et al. 2005). Previous studies have shown that 
cocktail supplemented with Epidermal growth factor (EGF) (Bhora et al.1995) , 
Insulin (Fritsche et al. 1991)Kamalati et al.1989) , Fibroblast Growth Factor (FGF) 
(Rubin et al.1995)  , Transforming growth factor (TGF) superfamily member bone 
morphogenetic protein-4 (BMP-4) (Aberdam 2004), Angiopoietin related Growth 
Factor (AGF) (Ji et al. 2006), Granulocyte/Macrophage Colony Stimulating factor 
(G/M CSF) (Braunstein et al.1994), Growth Differentiation Factor-5 (GDF-5) 
(Metallo et al. 2008), Thymocyte Activating Factor (Thaller & Eichele 1987), Tumor 
Necrosis Factor-α (Kawakami et al. 2005), Interleukin-1 (Bamberger et al. 2002) and 
Nerve Growth Factor (NGF) (Li et al. 2005) enhance the primary keratinocyte 
growth. Among all protein based growth factors, cytokines and chemicals as 
mentioned above, effect of BMP-4 in hESC differentiation into keratinocyte lineage 
has been addressed in more detail. BMPs belong to family of TGF-ß superfamily. 
Previously, it has been shown that during gastrulation in chick and amphibian; BMP-
4 synergizes epidermal commitment in the ventral zone. Concurrently, BMP-4 
antagonists produced by Spemann- Mangold of dorsal zone enhance neurogenesis 
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(Muñoz-Sanjuán et al. 2002). Moreover, BMP-4 shows similar synergistic effect 
towards epidermal differentiation in vertebrate species (Pankratz et al. 2007). 
Additionally, it has been shown that BMP-4 increases the cytokeratin expression in 
P19 embryonal carcinoma cells (Metallo et al. 2008). Furthermore, BMP-4 also plays 
important role in the morphogenesis of cutaneous appendages at a later stage of 
development (Metallo et al. 2008). Therefore, using a  similar approach, Coraux et al. 
in 2003 reported first successful differentiation of mouse embryonic stem cells 
(mESCs) into keratinocyte lineage by using a medium supplemented with BMP-4 
(Coraux et al. 2003). However, a  low percentage of differentiated cells (around 20%) 
was found with keratinocyte-specific markers. Alternatively, Ji et al. in 2006 reported 
the first hESCs-Kert differentiation through Embryoid Bodies (EBs) by using 
exogenous application of Epidermal Growth Factor (EGF) (Ji et al. 2006).  In the 
same study, the potential of hESCs to undergo direct differentiation into a 
keratinocyte lineage on different feeder free substrates in defined keratinocyte 
medium was demonstrated. Ji et al. reported that direct differentiation of hESCs into 
the keratinocyte lineage was better than hESCs derived keratinocyte differentiation 
through EBs. In agreement with Ji et al. Aberdam et al. in 2008 reported the direct 
differentiation of hESCs into keratinocyte lineage  using inactivated PA6 stromal 
cells and mEF as feeder cells. Moreover, in this study, hESCs were exposed to  
medium supplemented with BMP-4, insulin and EGF. BMP-4 treatment was 
maintained for 3 days (Aberdam et al. 2008). However,  as in previous studies, 
Aberdam et al. were only able to achieve 20-25% differentiation efficiency through 
application of protein-based growth factors. Due to the high proportion of other 
differentiated cells from other lineages, sorting was required to get the pure 
population of hESCs-Kert; sorting compromises the cell survival and propagation. 
Therefore, there was a need of an alternative strategy which could be used to 
differentiate hESCs into pure population of keratinocytes. Therefore, the application 
of non-proteinaceous compounds was proposed.  
 
1.4.1.3 Application of non-proteinaceous compounds for hESCs differentiation 
to keratinocyte lineage 
 
In contrast to the protein-based growth factors; non-proteinaceous compounds have a 
longer survival. Therefore, their application is effective for several weeks.  
Additionally, unlike protein-based growth factors and cytokines, non-proteinaceous 
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compounds do not undergo post-translational modification and can be manufactured 
in a laboratory. Therefore, they are more chemically and structurally distinct 
compared to protein-based growth factors and cytokines. Moreover, it has been 
shown previously that non proteinaceous compounds promote primary keratinocyte 
growth and differentiation (Heng et al. 2005). They were first used in the  form of  
ascorbic acid (AA) in conjunction with  BMP-4  for short period (3 days) to drive  
mESCs and hESCs  towards keratinocyte lineage (Coraux et al. 2003, Aberdam 2004, 
Ji et al. 2006, Aberdam et al. 2008). Although the application of AA enhanced the 
differentiation efficiency, the protocol was hampered by the presence of a high 
percentage of non-keratinocytic cells in culture. However, Metallo et al. in 2008 used 
retinoic acid (RA) instead of AA in conjunction with BMP-4 for 7-10 days to direct 
differentiation of hESCs into keratinocytes in xenogeneic feeder free culture 
conditions  to obtain 89%-91% of hESCs-Kert (Metallo et al. 2008). Additionally, in 
the same study, it was reported that application of RA alone was found to be as 
effective as combined RA and BMP-4 application in producing a relatively pure 
population of hESCs-Kert at day 30. However, hESCs-Kert differentiated from this 
protocol were not able to survive for longer passages (Metallo et al. 2008).  
Expandable hESCs-Kert have great application potential, therefore in contrast to 
Metallo et al. ‘s feeder free system,  Guenou et al. in 2009  described a system in 
which hESCs-Kert were able to propagate  for 10 passages (Guenou et al. 2009). In 
this study, hESCs were co-cultured with NIH 3T3 feeder cell lines and were exposed 
to AA and BMP-4 for a prolonged culture period (40 days).  Guenou et al. were able 
to get 50-56% keratinocyte at day 40, followed by sorting of differentiated hESCs-
Kert from non-keratinocyte cells. Nevertheless, post sorting hESCs-Kert were able to 
grow for 10 passages without undergoing senescence, and formed a multilayer 
epithelium in vitro and in vivo.   
 
Overall, based on all previous reports related to hESCs-Kert, I can conclude that  
- Direct differentiation of hESCs was found to be more efficient than 
keratinocyte differentiation through EBs.  
- Combination of growth factors, cytokines and chemicals and non-
proteinaceous compounds were found to synergize the hESCs differentiation 
into keratinocytes as compared to growth factors cytokines and chemicals 
application only. 
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-  hESCs differentiation into keratinocyte lineage on feeder free system were 
found to yield relatively pure population compared to hESCs differentiation 
into keratinocyte on co-culture system.  
- hESCs-Kert differentiated in co-culture system were found to be more 
expandable  as compared to hESCs-Kert differentiated on feeder-free system.  
The above literature review on hESCs differentiation into keratinocyte lineage has 
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Table 3: Summarization of different techniques used to differentiated hESCs 
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1.5 Application of hESCs-Kert 
 
hESCs-Kert hold great potential for future clinical and therapeutic use, basic research 
and industrial applications due to their  availability in real time. The applications are 
described in more detail below. 
1.5.1 Clinical and Therapeutic Applications of hESCs-Kert 
 
Skin is one of the largest organs of the body and acts as the primary barrier between 
the external environment and the deeper tissues. However, conditions such as foot 
ulcers, skin defects and massive burns often result in open wounds and require rapid 
surgical closure with appropriate materials (Izumi et al.2003). Surgical closures with 
autologous epidermal grafts are ideal but can be used only to cover burns less than 
30% of the total body surface area. However, in case of full thickness burns or burns 
that cover more than 75% of total body surface area requires immediate treatment 
with epidermal grafts, autologous epidermal grafts are hampered with donor site 
morbidity, time constraint and limited cell yield from primary explanted 
keratinocytes. Genzyme Biosurgery (Epicel) is the only company which offers 
therapeutic products of autologous cell origin (Mason 2005) but they are expensive 
and not available to treat patient immediately. Allogeneic ‘readymade’ skin grafts are 
cost effective and can be used as an alternative treatment option.   
1.5.1.1 Allogeneic tissue-engineered ‘off-the-shelf’ epidermal grafts 
 
Because of the various limitations associated with utilizing autologous skin grafts as 
discussed in the previous section, tissue-engineered ‘off-the-shelf’ epidermal grafts 
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1.5.1.1.1  Allogeneic primary keratinocytes as a source for ‘readymade’ 
epidermal grafts 
 
Current clinical practice to treat severely burn patients is to use cadaver epidermal 
grafts supported with an allogeneic dermal layer (De Luca et al. 2006).  These 
allogeneic epidermal grafts can be removed easily at later stages leaving behind the 
dermal bed on which autogeneic epidermal grafts are placed once they are ready for 
application. However, production of autogeneic grafts on a large scale is questionable 
as discussed in the previous section. Alternatively, in conditions like epidermal ulcers 
associated with  sickle cell anemia, arterial defects, diabetic mellitus, epidermolysis 
bullosa etc.,   application of allogeneic epidermal grafts is a more feasible treatment 
option (Jones & Nelson 2007, Fivenson et al. 2003). 
 Recently, the U.S. Food and  Drug Administration (FDA) has approved one 
commercial product from Organogenesis (Apligraft) for the treatment of the above-
mentioned conditions. Apligrafts consist of allogeneic primary adult keratinocytes 
over human fibroblasts. However, these allogeneic epidermal grafts are associated 
with the risk of potential rejection which may lead to the failure of  the grafts 
(Metcalfe & Ferguson 2007, Lemaître et al. 2011). The downstream cascade involves 
the donor’s dendritic cells (DCs) migration to the recipient draining lymph nodes to 
present the donor antigens via two mechanisms: direct pathway and indirect pathway. 
The direct pathway involves the recognition of donor’s major histocompatibility 
complex (MHC) on donor’s DC by recipient’s T cells. Alternatively, the indirect 
pathway involves the recognition of donor peptides on self-MHC molecules by 
recipient NK cells resulting in direct killing of therapeutic cells through the 
production of pro-inflammatory cytokines including  (Tumor Necrotic Factor alpha) 
TNF-α and Interferon gamma (IFN-γ) (Miller 2008). Activation of lymphocytic cells 
via direct or indirect mechanism triggers the acute and chronic rejection of allogeneic 
epidermal grafts. 
 Therefore, the current challenge in this field is to mitigate this immune response 
either by reducing the inflammation process, altering the immunogenicity of 
therapeutic cells and/or applying immunosuppressant drugs. Although, the 
introduction of immunosuppressant drugs has reduced the risk of acute and chronic 
transplant rejection of allogeneic epidermal grafts to some extent, the use of 
immunosuppressive drugs is associated with many side effects such as malignancies, 
metabolic disorders and opportunistic infections. Therefore, keratinocytes with 
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reduced or minimum immunogenicity may be an alternative to prolong the survival of 
allogeneic epidermal grafts with the minimum use of immunosuppressive drugs. 
Therefore, hESCs-Kert may appears to be  a good alternative for future clinical 
application. 
 
1.5.1.2 hESCs-Kert as an alternative cell source for potential clinical 
applications  
 
For the last decade, hESCs have been suggested as a substitute for keratinocytes due 
to their self-renewal and immortality. In contrast with primary keratinocytes, hESCs 
have potential to offer unlimited supply of keratinocytes for large scale production of 
allogeneic epidermal grafts in a shorter time under good controlled laboratory 
practice.  
1.5.1.2.1 Concerns associated with the use of hESCs-Kert for clinical 
applications 
 
Clinical application of hESCs-derived allogeneic epidermal grafts is associated with 
three main concerns; 
a)  Immunogenicity  
b) Tumorigenicity  
c) Introduction of xenogeneic components  
a) Immunogenicity  
  
Recently, Guenou et al.  in 2009 have reported that hESCs-Kert express low levels of 
human MHC class I (HLA-ABC) as compared to primary keratinocytes (Guenou et 
al. 2009). Moreover, it has been  proposed that hESCs banked with three major 
Human Leucocyte Antigen loci (HLA) (HLA-A, HLA-B, HLA-DR) should be 
sufficient for matching recipient’s grafts to  overcome the risk of immunogenicity 
(Taylor et al. 2005, Nakajima et al. 2007, Nakatsuji et al. 2008). Additionally, down-
regulation of MHC expression of hESCs may be an alternative treatment option to 
reduce antigenicity and support graft acceptance (Trounson 2002).  





Tumorigenicity is another major obstacle associated with clinical application of 
allogeneic hESCs derived epidermal grafts. hESCs tend to form a tumor called a 
‘teratoma’ after in vivo implantation. However, a teratoma is a non-malignant tumor, 
formed by disorganized differentiation and proliferation of pluripotent SCs. 
Nevertheless, teratomas can be potentially dangerous if implanted in patients, 
therefore full screening of pluripotent markers, karyotyping and genomic integrity 
expression is required before their potential clinical use. However, due to the 
superficial placement of hESCs-derived epidermal grafts,  it is relatively easy to 
detect any abnormal proliferation and the grafts can be removed surgically (Lemaître 
et al. 2011).  
c) Introduction of xenogeneic components during hESCs differentiation into 
keratinocyte lineage  
 
To date, the strategies used for the induction of hESCs towards the keratinocyte 
lineage involved the use of xenogeneic components such as feeder cells, and/or 
extracellular matrix (ECM) (Green et al. 2003, Aberdam 2004, De Luca et al. 2006, 
Iuchi et al. 2006, Ji et al. 2006, Aberdam et al. 2008, Hewitt et al. 2009, Metallo et 
al. 2008, Guenou et al. 2009). The presence of  these xenogeneic components  in 
culture environment limits the clinical application of hESCs due to the potential risk 
of transmission of animal pathogens and viral or bacterial infections (Cobo et al. 
2005, Sjögren-Jansson et al. 2005, Skottman & Hovatta 2006, Rajala et al. 2010). 
Furthermore, it has been shown that exposure of hESCs to animal components in 
culture systems causes higher expression of immunogenic agents (e.g., N-
glycolylneuraminic acid and Neu5Ac) by the  hESCs (Martin et al. 2005, Heiskanen 
et al. 2007). Clearly, there is a need to eradicate or at least minimize the exposure to 
xenogeneic components in the differentiation protocols so as to enhance the potential 
for  clinical application of hESCs derived somatic cells (Peng et al. 2012, Mallon et 
al. 2006)  
Although, to date, hESCs-Kert has not been reported in any clinical trial, many 
clinical trials with other hESCs progenitors are currently ongoing. The first hESCs 
clinical trial in humans was conducted in January 2009, by Geron Corporation of 
Menlo Park, CA. In this study, hESCs were used to repair injured spinal cord. 
However, the clinical trial was stopped in July 2012 due to financial decision of the 
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company. Moreover, in March 2011, FDA approved the use of hESCs-derived retinal 
cells for clinical trial (Funded by Advanced Cell Technology). This study involves 
the injection of hESCs-derived retinal cells in ten volunteer patients, suffering from 
genetic eye disease. The preliminary results were promising and no sign of any 
clinical problem were reported (Schwartz et al.2012). Additionally, in France, 
Ménasché Pucéat and Philippe Michel group is trying to get approval from French 
health authorities to use hESCs-derived cardiac cells for clinical trial. This study will 
involve the treatment of heart failure by depositing hESCs-derived cardiac cells on 
biomaterial scaffold (Embryonic Stem Cell Clinical Trials: Humans Therapies 2011). 
Hence, hESCs-Kert hold great clinical potential. Therefore, it was of my interest to 
address the concerns associated with clinical application of hESCs-Kert to enhance 
their potential clinical application in regenerative medicine and dentistry. 
 
1.5.2 hESCs-Ker as a research model for immune response  
 
Oral mucosa comprises of outer keratinized or non-keratinized ‘epidermis’ and inner 
connective tissue ‘dermis’. The epidermis has been portrayed to have multiple 
functions in protecting our internal systems against various assaults from the outside 
environment (Chuong et al.2002). In last two decades, researchers have also started to 
appreciate the biologically active role that the epidermal immune system plays in 
defending our body against external pathogens (McKenzie & Sauder 1990).  
Keratinocytes are the building block of epidermis and may play a vital role in 
establishing an epidermal immune response (Williams & Kupper 1996). Therefore, it 
is no surprise that in recent years cultured keratinocytes from different sources have 
been employed as in vitro research models for studying and understanding the 
epidermal immune response. 
 
To date, the most widely used in vitro research models include mouse keratinocytes, 
immortalized human keratinocyte cell lines and cultures of primary human 
keratinocytes (Christensen & Haase 2012, Meyer et al. 2011, Meyer-Hoffert & 
Schröder 2011, Romano & Sinha 2011, Aubdool & Brain 2011, Garner et al. 2011). 
The animal-derived models are easily available and have contributed a lot to our 
understanding of human keratinocytes. However, their potential in basic and applied 
research is limited by the existence of substantial differences from the human 
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counterpart(Banks-Schlegel & Harris 1983, Boukamp et al. 1988, Supp et al. 2004). 
Therefore, conclusions drawn from animal data remain questionable and usually 
require further validation (Poumay & Coquette 2007). Primary human keratinocytes 
help in overcoming  this problem. However, their use is severely hindered by very 
high donor variability, low availability, possible patient morbidity and low 
proliferative capacity (Zghoul et al. 2001, Olaru & Jensen 2010). Thus, immortalized 
human keratinocyte cell lines such as HaCaT and NIKS have emerged as extensively 
used research models. However, these cells have conferred genetic abnormalities, 
such as isochromosomes or mutations in master regulatory genes like p53, which 
contribute to some non-negligible cytogenetic and phenotypic differences exhibited 
(Schoop et al. 1999, Maas-Szabowski et al. 2003, Chapman et al. 2010). Thus, there 
is a need of a new research model to overcome these limitations as previously 
mentioned. To the best of my knowledge,  hESCs-Kert have never been reported as 
research model.Therefore, I proposed hESCs as an alternative, unlimited cell source 
to obtain consistent, human origin, expandable and ‘off-the-shelf’ keratinocytes 
which may be used as a reliable research model. 
 
1.5.3 hESCs-derived multilayer epithelium (hESCs-MLE): a permeability 
testing model for industrial application 
 
The keratinized multilayered epithelium which covers the exterior of the body and 
areas of the oral cavity forms a protective barrier against mechanical damage and 
penetration by microorganisms, exogenous toxins and antigens. On the other hand, 
effective local delivery of therapeutic compounds requires penetration across the 
superficial permeability barrier, which is located in the keratinized layer (Stratum 
Corneum (STC)) of the tissue.   The development of an in vitro model that can 
reproduce the appropriate mechanical and permeability characteristics of the normal 
tissue may be critical to the formulation and delivery of therapeutic compounds and 
to studies of pathogenesis of microbial diseases, ranging from periodontal disease to 
AIDS, which involve epithelial penetration by bacteria or virus.  
 Ex vivo human tissue biopsies or surgical specimens can be used to study 
permeability and barrier properties of skin and oral mucosa but there are numerous 
difficulties associated with such sources. It is difficult to obtain sufficient, normal, 
healthy tissues. Moreover, there are also differences in permeability depending on 
age, gender and ethnicity (Lampe et al. 1983).  Additionally, ethical considerations 
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also limit the quantity or frequency with which tissue can be obtained and there may 
be risks of infection (Table 4).   
 Traditional small animal models such as rodents and lagomorphs have numerous 
drawbacks for studying barrier properties; their skin is thin and oral cavity is not the 
same in terms of anatomy and physiology as humans. Monkeys and pigs have very 
similar oral epithelium structure in terms of anatomy, physiology, metabolism and 
pathology to human but are very expensive to purchase and maintain (Wertz & 
Downing 1983). Although cell and tissue culture models (Table 4) can offer 
advantages in terms of availability of tissue, cost and safety but to date have a number 
of limitations. Cell culture monolayers do not show differentiation that accompanies 
stratification and thus do not show the barrier properties of the normal tissue. Certain 
cell lines (e.g. intestinal Caco-2) may show junctional complexes and a barrier typical 
of a simple epithelium but this is not the same as that present in a stratified tissue 
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Table 4: Comparison of model systems for studying permeability  
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The growth of stratified, differentiated human epithelium to form organotypic 
cultures potentially overcomes the disadvantages of cell monolayers (Table 4). 
However, in practice it has not proved easy to grow organ cultures that can 
effectively reproduce the barrier function of a normal tissue. For example, 
measurements of permeability of organotypic skin cultures showed permeability to a 
variety of compounds amounting to be 3-100 folds greater than for normal skin 
(Robert et al. 1997, Garcia et al. 2002, Barai et al. 2008). Nevertheless, organotypic 
cultures made up of human primary keratinocyte are most widely used models to 
date. Current in vitro organotypic models of  keratinized stratified tissue made up of 
primary keratinocytes may exhibit some of the structural characteristics of the human 
tissue but are expensive, highly variable due to batch  to batch  variation and do not 
reproduce the barrier properties of the parent tissue (Robert et al. 1997, Garcia et al. 
2002,  Barai et al. 2008) (Table 5). However, hESCs derived multilayer epithelium 
(hESCs-MLE) has never been reported for permeability studies. Therefore, hESCs-
MLE can offer an alternative, consistent, limitless and human in origin permeability 
research model to pharmaceutical and cosmetic industries (Table 5).  
 






Human primary cell 
lines  
- Inexpensive  
-  Easy to grow 
- Barrier depends on 
tissue conditions  






- Less variation  
- Limitless supply  
- Reproducible  
- Inexpensive 
- Barrier depends on 
tissue conditions 
 
Based on the above information, the overall, the aim of my study is to differentiate 
hESCs into keratinocyte lineage with the minimum use of xenogeneic components for 
their potential clinical application. Additionally, I also aim to investigate the immune 
response and permeability properties of hESCs-Kert and hESCs-MLE respectively 
for potential research and industrial applications. 
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1.5.4  Hypothesis  
 
The main hypothesis of my study is that hESCs can be used as an alternative source 
for derivation of relatively pure and expandable population of hESCs-Kert with the 
minimum use of xenogeneic components for potential clinical, research and industrial 
applications. To support this hypothesis:  
(a) hESCs should be able to differentiate into relatively pure and expandable 
population of hESCs-Kert without using xenogeneic substrate. 
 (b) hESCs-Kert should be able to respond in a similar way as other available in vitro 
research model when exposed to any pathological condition.  
(c) hESCs-Kert should be able to form keratinized multilayer epithelium (MLE) at air 
liquid interface with desirable permeability property.  
1.5.5 Aims and Objectives 
 
To test above hypothesis, sequential phases of studies were carried out with their 
respective objectives 
Phase 1: hESCs differentiation into clinically amenable hESCs-Kert  
During the first phase of my study I aim to minimize the use of animal components in 
the differentiation protocol so as to get a pure and expandable population of 
keratinocytes from hESCs in an autogeneic microenvironment. To achieve the aim of 
this phase of the study I devised a step-wise strategy:   
Step 1: hESCs were differentiated into feeder cells (autologous feeders: hESCs-ebF) 
through embryoid bodies (EBs)  
Step 2: hESCs were co-cultured on inactivated hESCs-ebF to establish an autogeneic 
co-culture system (ACC). 
Step 3: Optimization of in vitro conditions. 
Step 4: hESCs differentiation into keratinocyte lineage and characterization of 
hESCs-Kert. 
Step 5: Establishment and characterization of an autogeneic feeder-free system (AFF) 
derived from hESCs-ebF.  
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Step 6: Characterization of hESCs-Kert differentiated in AFF system.  
Phase 2: hESCs-Kert as an alternative research model for the study of immune 
response  
In the second phase of my study, I aim to use hESCs-Kert as an in vitro research 
model to investigate the immune respond in a pathological condition as compared to 
the keratinocytes. 
This phase involves the following steps: 
Step 1: Exposure of hESCs-Kert to P. gingivalis at different time periods. 
Step 2: Expression of different inflammatory cytokines and TLRs were analysed at 
mRNA level in the presence or absence of P. gingivalis. 
Step 3: Expression of NFK-B was analysed at protein level in presence and absence 
of P. gingivalis.   
Phase 3: hESCs-MLE: permeability testing model for industrial application 
In third phase, I aimed to use hESCs-MLE with appropriate barrier properties for 
permeability testing and as a potential model for industrial application. 
With the above-mentioned aim, following step-wise strategy was made 
Step 1: Construction of a hESCs-MLE in vitro. 
Step 2: Characterization of hESCs-MLE at morphological and molecular level.  
Step 3: Characterization of hESCs-MLE in terms of development of a permeability 
barrier
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2 Introduction to methods and materials  
 
To achieve my aims, sequential experiments were carried out to establish two 
autogeneic microenvironments (2.3 and 2.4), differentiation and characterization of 
hESCs-Kert (2.5.1 and 2.5.2) (Phase 1), to test the immune respond (Phase 2) and 
permeability functionality (Phase 3) of hESCs-Kert.  
2.1 Derivation of mouse embryonic fibroblast (mEF) 
 
The first report on the derivation of hESCs described mEF feeder layer as a necessity 
for their continuous growth in an undifferentiated stage (Thomson et al. 1998).  
Therefore, mEF were derived from mice embryos and were used as feeders to support 
hESCs culture as described.  
2.1.1 Extraction of mice embryos 
  
Isolation of mouse embryos was done as described previously (Xu 2005). Briefly, 
13.5 days pregnant CF-1 mice were sacrificed by CO2 suffocation. I chose Charles 
Farm (CF-1) mice as this strain was recommend for feeder fibroblast cells for routine 
expansion of hESC (Thomson et al. 1998). Additionally, CF-1 mice are inexpensive 
and readily available. The surface of the abdomens was disinfected with 70% ethanol. 
The uterine hons were exposed by cutting the peritoneal walls. The exposed uterine 




 free phosphate buffered saline (PBS) (1st 
Base)  before embryos release. Counting the number of embryos was followed by 
separation of the visceral tissues from the embryos. Embryos were then washed three 
times.  Prepared embryos were completely dissected by mincing with fine iris scissors 
for 10-15 minutes. Complete dissection of embryos was followed by addition of 5ml 
of 0.05% TE (Trypsin with ethylenediaminetetraacetic acid (EDTA), GIBCO) at 37°C 
for 10 minutes. I used TE because of its enzymatic properties and it cleaves proteins 
on the C-terminal sides of arginine and lysine residues (Ren et al. 2009).  After 
incubation of minced embryos in TE for 10 minutes, the vigorous pipetting was done 
and 5ml of fresh TE was added and were incubated for extra 10 minutes. Once the 
embryos were digested in TE buffer, 20ml of mEF derivation medium (Table 6) was 
added for neutralization. As TE cleaves protein therefore it was necessary to 
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neutralize the effect of TE through anti-trypsin. Anti-trypsin effect of serum is well 
established (Ren et al. 2009). Therefore, I used meF derivation medium 
supplemented with 10% FBS to neutralize trypsin. The cocktail of TE buffer, tissue 
mixture and mEF medium was transferred to 50ml falcon tube and centrifuged at 
300xg for 5 minutes to remove the supernatant. Fresh mEF medium was added to re-
suspend the tissue mixture and pated on 0.1% gelatin (Sigma) coated 75cm
2
 culture 
flasks (seeding density of 3 embryos per flask) and incubated at 37°C in a 5% CO2 
atmosphere with 95% humidity for three weeks. After three weeks, tissue mixture 
derived fibroblast like cells (mEF) were found. Upon 80% confluence, mEF were 
frozen in mEF freezing medium (Table 6) and cryopreserved in liquid nitrogen for 
storage. The composition of freezing medium was provided in Table 6. 
 
Table 6: Composition of mEF derivation medium and mEF freezing medium 
mEF derivation medium (1000ml) 
Dulbecco’s Modified Eagle (DMEM) medium (Sigma) 900ml 
Fetal Bovine Serum (FBS) (Biowest) 100ml 
Non-essential amino acids solution (Sigma) 10ml 
Penicillin-Streptomycin 100x solution (GIBCO/Brl) 10ml 
mEF freezing medium (100ml) 
DMEM Medium 70ml 
FBS 20ml 
Dimethyl sulfoxide (DMSO) (Sigma) 10ml 
 
 
2.1.2 Expansion of mEF  
 
After obtainining mEF from mouse embryos, expansion of mEF was done as 
described previously (Xu 2005). Briefly, mEF derivation medium was used for the 
propagation of mEF. mEF were grown for 3-4 passages with the splitting ratio of 1:5. 
Upon 90% confluence, mEF were trypsinised with 0.05% of TE buffer at 37°C for 5 
minutes. Trypsinization of cells was followed by neutralization of TE with mEF 
derivation medium. The cells were then transferred to 50ml falcon tube and 
centrifuged at 1200rpm for 8 minutes. The cells pellets were re-suspended in fresh 
mEF derivation medium and re-plated to new culture flask for expansion.  
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2.1.3 mEF mitotically inactivation    
 
It is recommended to use mitotically inactivated mEF as feeder for the expansion of 
hESCs as mitotically inactivation prevents feeder layers to undergo cell division and 
minimizes the xenogeneic contamination of hESCs differentiation (Thomson et al. 
1998). Inactivation of mEF was done as previously reported (Xu 2005). Briefly, the 
confluent mEF (passage 3 or 4) were mitotically inactivated by 10µg/ml mitomycin C 
(Kyowa) dissolved in Hank’s balanced salt solution (HBSS, Sigma) for 2 hours. After 
inactivation, mEF were washed with PBS three times. Cell washing was followed by 
their trypsinization by TE at 37°C for 5 minutes as described above (2.1.2). The mEF 
were re-suspended in mEF freezing medium and frozen at 1.4x10
6
/ml/vial. The 
frozen inactivated feeder cells were thawed at 37°C within 2 minutes and plated on 
0.1% gelatin pre-coated 6-well plate at a density of 1.5 x 10
5
 cells/well one day prior 
to hESCs passage. 
 
2.2 Expansion of hESCs 
 
The National Institutes of Health–registered H9 hESC line (Agreement no. 04-W094, 
WiCell Research Institute, Madison, WI) was used in this study. H9-hESCs were 
seeded on to mitotically inactivated mEF feeder cells in hESCs medium (1:1 
DMEM/F-12, supplemented by 20% knockout serum replacement, 1% non-essential 
amino acid, 1mM L-glutamine, 4 ng/mL FGF-2 and 0.1mM β-mercaptoethanol 
(Sigma, St Louis, MO)) as previously reported (Thomson et al. 1998). One of the 
most important rationales for using hESCs medium was to keep hESCs in an 
undifferentiated state along with their nutritive supplementation. Fetal bovine serum 
(FBS) considered as the best option for nutritive supplementation, however, FBS also 
contains factors which induce hESCs differentiation. Therefore FBS was replaced by 
defined, serum-free knockout serum (Gibco®) as reported previously (Thomson et al. 
1998).  When the cells become confluent, hESCs colonies were treated with 1mg/ml 
collagenase IV (GIBCO) for 3 minutes at 37°C followed by manual dissection using 
15ml falcon tube and centrifuged at 200xg for 5 minutes. The cell pellets were re-
suspended in fresh hESCs culture medium and seeded on inactivated feeder cells at 
1:6 splitting ratio every 5-7 days. All cells were cultured at 37°C with 5% CO2 
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atmosphere and 95% humidity. The medium was changed every day. All the media 
and components were obtained from Invitrogen unless otherwise noted.  
 
2.3 Generation of hESCs derived fibroblast (hESCs-ebF) as feeder 
cells for the autogeneic co-culture system (ACC system) 
 
For the establishment of autogeneic co-culture system (ACC system) hESCs-ebF 
were obtained from hESCs as previously reported (Fu et al. 2010). Briefly, hESCs 
colonies were dissociated into clumps by treatment with 1 mg/ml Collagenase Type 
IV and then transferred to non-adherent 6-well culture plates in embryoid body 
medium (80% DMEM/F12 and 20% knockout serum replacer (KSR), supplemented 
with 1 % non-essential amino acids, 1mM L-glutamine and 0.1 mM ß-
mercaptoethanol) for 5 days. After 5 days, hESCs were differentiated into embryoid 
bodies (EBs). EBs are three dimensional aggregates of hESCs.  hESCs derived  EBs 
were seeded on 0.1% gelatin coated 75cm
2
 plates in a DMEM-FBS medium (hESCs-
ebF differentiation medium: high-glucose DMEM (Sigma) supplemented with 10% 
FBS (Biowest, Caille,Nuaille)) for 3 weeks. The cells at this stage were named as 
hESCs-ebF passage 0. hESCs-ebF passage 0 were sequentially passaged until 
homogenous morphology was obtained. hESCs-ebF were grown for 10 passages. 
Based on my results, hESCs-ebF passage 8 was  mitotically inactivated and plated 
onto the gelatin coated six-well plate of approximately 1.4x10
5
 cells per well 
followed by hESCs seeding on the next day. The hESCs – hESCs-ebF autogeneic co-
culture system (ACC system) was kept in hESCs medium for 2-3 days before the start 
of differentiation.  
 
2.3.1 Characterization of hESCs-ebF 
 
Detailed characterization of hESCs-ebF has been reported previously by (Fu et al. 
2010). Therefore, I did basic characterization of hESCs-ebF at mRNA level (2.3.1.1) 
to confirm their fibroblastic lineage. Therefore, hESCs-ebF were grown for 10 
passages. 
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2.3.1.1 Reverse transcriptase - Polymerase Chain Reaction (RT-PCR) 
analysis 
 
RT-PCR was done as previously reported (Fu et al. 2010). Briefly, cells were 
harvested and spun down at 300xg for 5 minutes. Residual medium was removed and 
cells were washed with PBS. The pelleted hESCs-ebF were subjected to RNA 
extraction using RNeasy Mini Kit (Qiagen), following the manufacturer’s 
instructions. The concentration of RNA was read by Nanodrop ND-1000 
spectrophotometer (Nanodrop technologies). For cDNA synthesis, 500ng of total 
mRNA per 20ul reaction volume of each sample was reverse-transcribed into cDNA 
using iScript cDNA synthesis Kit (Bio-Rad). The reaction mixture contained 4µl of 
5xcDNA synthesis buffer, 1µl of iScript enzyme mixture, 500ng of mRNA samples 
and RNase-free water. The cDNA synthesis was carried out in thermal cycler 
(MyCycler
TM
 BioRad) with the following protocol: 5 minutes at 25⁰C, 30 minutes at 
42⁰C, 5 minutes at 85°C and held at 4⁰C. The obtained cDNA samples were subjected 
to PCR amplification for 35 cycles (Denaturing: 95⁰C, 30 seconds; Annealing, 45 
seconds; Extension: 72⁰C, 60 seconds) followed by final extension at 72°C for 10 
minutes and held at 4⁰C. The component of the PCR reaction mixture are listed in 
Table 7. The amplified genes and the corresponding primers were listed in Table 7.  
ß-Actin served as a loading control.   
 
The amplified PCR production were loaded onto 2% agarose gel and subjected to 
electrophoresis for 35 minutes at 65 volts. The DNA bands were visualized by 
ultraviolet (UV) illumination and the images were capture by universal hood II 
(BioRad).  
Table 7: Components of RT reaction mixtures 
 Components Volume (µl) 
5x Green GoTaq® Flexi Buffer (Promega) 4 
GoTag® Flexi DNA Polymerase (Promega) 0.1 
25mM MgCl2 (Promega) 1.2 
Forward primer (1st Base) 0.4 
Reverse primer (1st Base) 0.4 
dNTP (Promega) 0.4 
cDNA Template  1 
Distilled and deionized H2O (ddH20) 12.5 
Total Volume 20 
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2.3.1.2 Enzyme-linked immunosorbent assay (ELISA) 
 
Previously, hESCs-ebF were used to establish an autogeneic co-culture system (ACC) 
for the propagation of undifferentiated hESCs (Fu et al. 2010). However, the use of 
ACC system for keratinocyte differentiation has never been reported. Therefore, it 
was of my interest to optimize in vitro conditions and select the most appropriate 
passage number of hESCs-ebF which could be used to establish an ACC system for 
the keratinocyte differentiation.  Therefore, based on thee results, expression of 
Keratinocyte Growth Factor I (KGF-I) by  passage 5 to passage 10 of hESCs-ebF was 
analysed by ELISA by using the following protocol. 




 in 6-well plate 
containing fibroblast differentiation medium. Cells were allowed to get confluent and 
were mitotically inactivated by 10µg/ml mitomycin C in HBSS for 2 hours. After the 
treatment, the inactivated solution was removed from the plate. The adherent cells 
were washed with PBS twice and then incubated with 5ml of fresh fibroblast 
differentiation medium. The medium conditioned by inactivated hESCs-ebF were 
collected 4 days after the incubation, transferred to 15ml falcon tubes, lyophilized 
overnight at -80°C and frozen at -20°C before analysis. For ELISA analysis, the 
lyophilized conditioned medium were dissolved in 1ml of PBS and keratinocyte 
growth factor I (KGF-I) level was quantified by  using DuoSet® ELISA 
Development System (Catalog # DY251, R&D systems) as per the manufacturer’s 
instructions. Absorbance of each well was measured at 450nm.  
Normalized level of KGF-I = concentration of KGF-I/ concentration of total protein 
extract. 
2.3.1.3 Immunofluorescence staining  
 
Based on ELISA results, passage number of hESCs-ebF suitable for the establishment 
of an ACC system for keratinocyte differentiation was selected. Immunofluorescence 
staining was done to confirm the fibroblastic lineage of a selected passage number of 
hESCs-ebF (passage 8) at protein level by using following protocol.  
hESCs-ebF passage 8 were assessed for fibroblast (Fibronectin) and keratinocyte 
(K18 and K14) markers by immunofluorescence staining as reported previously (Fu 
et al. 2010). hESCs-ebF were cultured in a 24-well plate and were washed with PBS 
for 5 minutes. Samples  were fixed for 15 min in 4% paraformaldehyde at room 
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temperature (RT), permeabilized with 0.4% Triton X-100/PBS  for 10 min and 
blocked with PBS containing 4% BSA (Sigma) for 1 hour at room temperature (RT). 
The cells were incubated overnight at 4°C with the primary antibody (1:100) (Table 
10). Samples were washed with washing buffer supplemented with Tween 20 
(PBS/0.05% Tween 20) for 5 minutes twice. I used Tween-20 as it is a nonionic 
polyoxyethylene surfactant that is most frequently used as detergent for washing to 
get quality results. Washing was followed by the incubation of samples in secondary 
antibody (1:100) (Table 10) for 1 hour at RT in the dark. The cells were washed with 
washing buffer for 5 minutes twice and then mounted with slow fade gold anti-fade 
reagent containing DAPI (Invitrogen) to localize the nucleus. All the staining results 
were examined under Olympus IX70 fluorescence microscope.  
2.3.1.4 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2Htetrazolium  (MTS)  Assay 
 
After characterization of hESCs-ebF, it was necessary to optimized medium condition 
of autogeneic co-culture system (ACC) as hESCs and hESCs-ebF require different 
culture conditions. Therefore, MTS assay was done to test the viability of these cells 
in different media conditions. For MTS assay CellTiter 96® AQueous One Solution 
Cell Proliferation Assay Kit was used as per manufacturer’s instruction to analyse 
optimized in vitro conditions. Absorbance at 490nm was recorded. Briefly, cells were 




. Samples were kept in 
different medium conditions. Cell viability was analysed with MTS assay and 
evaluated by a plate reader at the absorption wavelength of 490nm.   
 
2.4 Extraction of ECM from hESCs-ebF for the autogeneic feeder 
free system (AFF system) 
 
To enhance the clinical application of hESCs derived keratinocyte (hESCs-Kert), I 
established hESCs derived feeder free system (autogeneic feeder free system) as 
previously reported (with slight modification) (Fu et al. 2011). Briefly, hESCs-ebF 
cells were seeded on 6-well plates at a density of 2.5x10
5
 per well of 6-well plate and 
kept overnight in hESCs-ebF differentiation medium. Next day, the hESCs-ebF 
differentiation medium was replaced with crowding medium i.e.DMEM, 0.5% FBS, 
50 mg/mL ascorbic acid (AA) (Sigma), 100mg/mL of dextran sulfatte (DS) (Sigma) 
Materials and Methods 
38 
 
supplemented with or without 25ng/ml recombinant human Activin (Catalog # 338-
AC, R&D Systems) for 3-5 days at 37°C followed by overnight incubation at - 80°C. 
Next day the plate was thawed at RT and each well was rinsed with PBS three times 
to get rid of cell debris to establish the AFF system. hESCs were seeded onto the AFF 
system in an animal-component free mTeSR
TM
 2 (StemCell Technology) medium for 
2-3 days before the start of differentiation. 
 
2.4.1 Characterization of ECM  
 
Characterization of hESCs-ebF derived ECM has been reported previously (Fu et al. 
2011). However, effect of Activin on hESCs-ebF derived ECM (AFF system) in the 
presence of crowders has never been addressed. Therefore, the rationale of the 
following experiments were to analyse the effect of Activin on hESCs-ebF derived 
ECM 
2.4.1.1 Fluorescence confocal microscopy 
 
Fluorescence confocal microscopy was done as previously mentioned (Fu et al. 
2011). Briefly, the ECM was fixed on the non-coated 4-well cover glass chambers 
(lab-Tek) with 4% paraformaldehyde (Sigma) at RT for 15 minutes. The samples 
were washed twice with PBS for 5 minutes, blocked with PBS containing 5% normal 
goat serum (Vector Laboratories) and 2% BSA (Sigma) for 1 hour at RT. The ECM 
were incubated with primary antibodies (Table 10) diluted in 1:200 in staining buffer 
(2% BSA in PBS) at 4°C overnight. Samples with no primary antibodies were taken 
as negative control. After overnight incubation, the ECM on glass slides was washed 
twice with washing buffer (PBS/0.05% Tween20) for 5 minutes. The ECM were 
incubated in secondary antibodies (Table 10) diluted at 1:100 in staining buffer 1 
hour at RT in darkness. The chamber was examined under confocal microscope 
(Olympus Fluoview FV1000).  The digital images were capture and analysed using 
FV10-ASW 2.0 Viewer software. The 3-D images were constructed using Imaris 3D 
interactive image visualization software (Bitplane Scientific software). 
2.4.1.2 Scanning electron microscopy  
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The scan electron microscopy was done as previously reported (Kalra et al. 2013). 
Briefly, the ECM-coated glass slides were fixed in 10% formalin and then dried in 
ascending alcohol concentrations.  Samples were dehydrated in a critical point dryer 
and sputter coated with gold under vacuum and examined in scanning electron 
microscope (XL30 FEG SEM, FEI, Philips). 
The ECM-coated glass slides were fixed with 2.5% glutaraldehyde in PBS for 4 
hours, followed by 1% osmium tetroxide treatment for 1 hour. ECM-coated glass 
slides were washed three times for 10 min with PBS. Then, the specimens were 
dehydrated in increasing concentrations of ethanol in the following manner 
1 25% ethanol - 5 mins 
2 50% ethanol - 10 mins 
3 75% ethanol - 10 mins 
4 95% ethanol - 10 mins 
5 100% ethanol - 3 x 10 min changes 
Following dehydration, the specimens were dried in a critical point dryer (CPD30 
Baltec; Leica, Guyancourt, France), mounted onto aluminum scanning electron 
microscopic stubs, and sputter coated with gold-palladium for 60 s under vacuum. 
Specimens were imaged using SEM (XL30 FEG SEM, FEI, USA), operated at an 
accelerating voltage of 10 kV. 
 
2.5 Keratinocyte differentiation in an autogeneic 
microenvironment for potential clinical application (Phase 1) 
 
After the establishment of an autogeneic microenvironments i.e. autogeneic co-
culture system (ACC)  in which hESCs derived fibroblast (hESCs-ebF) were used as  
feeders and  autogeneic feeder free system (AFF) in which hESCs-ebF derived ECM 
was used as a substrate;  hESCs were differentiated into keratinocyte lineage in these 
autogeneic microenvironments. For better understanding, hESCs-Kert differentiated 
in ACC system were named as “hESCs-KertACC”. Concurrently, hESCs-Kert 
differentiated in AFF system were named as “hESCs-KertAFF”. Moreover, 
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characterization was done at different time points at mRNA and protein level to 
confirm the keratinocyte lineage of differentiating cells. 
 
2.5.1 Keratinocyte differentiation in the ACC system (hESCs-KertACC) 
 
hESCs were co-cultured on mitotically inactivated hESCs-ebF (ACC)  and kept in 
hESCs medium for 3 days. For keratinocyte differentiation in the ACC system, hESC 
medium was replaced by F12 And Dulbecco medium (FAD medium) (mixture of 3:1 
of Dulbecco’s modified Eagle’s medium (DMEM) and Ham’s F12 media 
supplemented with 50 µg/ml AA (Sigma), 2% FBS, 5 μg/ml insulin, 10ng/ml 
recombinant human epidermal growth factor and 0.5µM of retinoic acid (RA)) for 20 
days. Additionally, 25ng/ml of Activin was introduced at day 9 until day 11 (3 days) 
from the day of differentiation. After 20 days the differentiated cells were detached 
and seeded on human Collagen Type IV coated flasks and kept in keratinocyte 
defined serum free medium (DSFM) without Activin and RA. 
 
2.5.2 Keratinocyte differentiation in the AFF system (hESCs-KertAFF) 
 
For keratinocyte differentiation of hESCs in the AFF system, animal-free mTeSR
TM
2 
medium was replaced by differentiation medium (DSFM supplemented with 1µM of 
RA) and applied for 10 days. The differentiated cells were sub cultured on human 
Collagen Type IV coated plates and kept in DSFM without RA.  
Keratinocyte cell lines HaCaT was taken as control. Control cell line was grown in 
DMEM medium supplemented with 10% FBS. 
 
2.5.3 Characterization of hESCs-Kert   
 
hESCs-Kert were characterized at different time point at mRNA and protein level to 
confirm their ectodermal lineage. 
2.5.3.1 Reverse transcriptase (RT) PCR and real-time RT-PCR analysis 
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hESCs-Kert were characterized at mRNA level by RT-PCR and real-time RT-PCR 
analyses. RT-PCR was performed by using the similar protocol as mentioned in 
2.3.1.1. 
Real-time RT-PCR was done as previously reported (Fu et al. 2011). Briefly, the 
reactions were performed using SYBR Green PCR Master Mix System (Applied 
Biosystems) and processed on StepOnePlus™ real-time RT-PCR system (Applied 
Biosystems). The components of the real-time RT-PCR reaction mixture are listed in 
Table 8. Expression of ß-Actin was used as the reference gene. Expression level of 
each target gene was then calculated as 2
∆∆Ct
 as described. A melting curve was used 
to verify the PCR products (Table 9). 
 
Table 8: Components of real time RT-PCR master mix 
Components Volume (µl) 
SYBR Green PCR Master Mix 10 
Forward primer (1st Base) 0.4 
Reverse primer (1st Base) 0.4 
cDNA 1 
Distilled and deionized H2O (ddH20) 8.2 
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Forward Primer Reverse Primer Amplic
on size 
sox1 NM_005986.2 5'-caa tgc ggg gag gag aag tc-3' 5'-ctc tgg acc aaa ctg tgg cg-
3' 
464 
pax 6 NM_000280.3 5'-ggc agg tat tac gag act gg-3' 5'-cct cat ctg aat ctt ctc cg-3' 427 





5'-gga aaa caa tgc cca gac tc-3' 5'-gtg gaa tac gtc cag gtg gc-
3' 
294 
k14 NM_000526.4 5'-gac cat tga gga cct gag ga-3' 5'-att gat gtc ggc ttc cac ac-3' 157 
hOct4 NM_001173531
.1 
5'-cgt gaa gct gga gaa gga gaa gct 
g-3' 
5'-aag ggc cgc agc tta cac atg 
ttc-3' 
246 
nestin NM_006617.1 5'-tgaagggcaatcacaacagg-3' 5'-tgaccccaacatgacctctg-3' 136 
TERT NM_001193376
.1 
5'-agctatgcccggacctccat-3' 5'-gcctgcagcaggaggatctt-3' 185 
β Actin NM_001017992
.2 





5’-gggcattccaacctt-3’ 5’-agctcggcgccctctgtgtag-3’ 440 
IL-6 NM_000600.3 5'- ggctcattctgccctcgagcc-3' 5'- ggaccgaaggcgcttgtggag -
3' 
100 
IL-8 NM_000584.3 5'- aagccaccggagcactccata-3' 5'- gaaggctgccaagagagccacg-
3' 
154 
iNOS NM_000625.4 5'- cgtgttcccccagcggagtg-3' 5'- acacgggggtgatgctccca -3' 692 
TLR-2 NM_001173531
.1 
5'-tgc tcg gcg ttc tct cag gtg-3' 5'-gat gac ccc caa gac cca cac 
ca-3' 
230 
TLR-4 NM_138554.3 5’- ccaattgctgtggggcggct-3’ 5’- aggaaccacctccacgcaggg-
3’ 
233 
TLR-5 NM_000918.3 5'- cgc ttt tgc gtc cgg gag gag-3' 5'-  tcc agg ttc gga cag cgc 
ca-3' 
440 
TLR-9 NM_003380.3 5'- ccc cca gca tgg gtt tct gcc-3' 5'- agg gcc tcc agt cgc ggt 
ag-3' 
165 
TNF-α NM_000224.2 5'-agc cgc atc gcc gtc tcc ta-3' 5'-cag cgc tga gtc ggt cac cc-
3' 
163 
Filaggrin  NM_002016.1 5’cagtgaggcatacccagagg’3 5’tgccacgtgactgtattcct’3 242 
Involucrin NM_005547.2 5'-tgcccacaaagggagaagta-3' 5'-gggttggcactggacaataa-3' 266 
K10 NM_000421.3 5'-gctcttttagccgtgggag-3' 5'-ttgattcttccagagcccga-3' 348 
K4 NM_002272.3 5'-ccctgtcacttctctgatagctc-3' 5'-gatgcttttgttccccctgag-3' 226 
c-myc NM_002467.4 5'-ctggaacttacaacacccgag-3' 5'-cctcctcgtcgcagtagaa-3' 263 
K19 NM_002276.4 5'-cagcttctgagaccagggttg-3' 5'-aggttctgcatggttagcttc-3' 304 
K17 NM_000422.2 5'-ctcctccagctccatcaagg-3' 5'-tcttcacctccagctcagtg-3' 320 
K5 NM_000424.3 5'-ggatgatccagaggctgagag-3' 5'-tgtgacaacagagatgttgactg-3' 314 
K1 NM_006121.3 5'-cactctaccaagcagagttgtc-3' 5'-ctgatggactgctgcaagtt-3' 331 
K76 NM_015848.4 5'-acttctggaggaagtggcta-3' 5'-ctgtccaaagtaaggggcca-3' 346 
K4 NM_002272.3 5'-ccctgtcacttctctgatagctc-3' 5'-gatgcttttgttccccctgag-3' 226 
K9 NM_000226.3 5'-gaccctcaatgacatgcgtc-3' 5'-ctgggcctccaagttactga-3' 304 
K13 NM_002274.3 5'-ccttaaatctgcctggcgtc-3' 5'-gaaaccaaagcgtatccaggt-3' 219 
K16 NM_005557.3 5'-ttcttcccgcgaggtcttc-3' 5'-gctttattagcccaccaccag-3' 245 
K17 NM_000422.2 5'-ctcctccagctccatcaagg-3' 5'-tcttcacctccagctcagtg-3' 320 
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2.5.3.2 Immunofluorescence, Confocal Microscopy and Flow cytometry  
 
To confirm my RT-PCR and real-time PCR results, I did characterization of hESCs-
Kert at protein level. Immunofluorescence staining was done as described in 2.3.1.3. 
Confocal microscopy was done as described in 2.4.1.1.  
For quantitative analysis of hESCs-Kert Flow cytometry was performed as previously 
reported (Fu et al. 2011). Briefly, hESCs-Kert were scrapped down after the 
collagenase IV treatment. Cells were dissociated into single cells and were fixed with 
4% paraformaldehyde for 1 hour at 4°C and permeabilized in PBS containing 0.25% 
Tween-20 at 37°C for 15 minutes. After being washed with PBS once, the cells pellet 
was suspended in 100µl staining buffer (4% BSA in PBS) containing primary 
antibody (Table 10) diluted at 1:200. The cells were incubated at 4°C for 2 hours. 
After incubation, 1ml of staining buffer was added and the cell suspension was 
centrifuged (300xg, 5 minutes, 4⁰C).  Supernatant was discarded and the wash 
repeated.  The cell pellets were then re-suspended in 100µl staining buffer containing 
secondary antibody (Table 10) diluted at 1:100 concentration for 15 minutes at 4°C in 
darkness. The cells were washed twice and re-suspended in 1ml of MACS
®
 buffer 
solution (Miltenyi Biotec). The percentage of respective markers were analysed by 
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Antibody Source Catlog # and 
Company 
References  
Primary Antibody mouse anti human 
K18 
sc-6259 (DC-10)  
Biotechnology, Santa 
Cruz, CA, USA 
(González et al. 
2011) 
Primary Antibody mouse anti human 
K14 
sc 58724 (LL002), 
Biotechnology, Santa 
Cruz, CA, USA 
(Sardella et al. 
2012) 




Cruz, CA, USA 
(Liu et al. 2011) 




Cruz, CA, USA 
(Jezierski et al. 
2010) 






(Fu et al. 2011) 





Sigma, MO, USA 
(Fu et al. 2011) 





(Fu et al. 2011) 
Primary Antibody           
 
mouse anti human 






et al. 2009) 
















(Fu et al. 2011) 
Secondary 
Antibody 
Alexa Fluor 594 
goat anti-rabbit IgG 
A11037; Invitrogen, 
CA, USA 
(Fu et al. 2011) 
Secondary 
Antibody 
HRP Conjugated  
goat anti-mouse  
170-6516; BIO-RAD, 
CA, USA 




HRP Conjugated  
goat anti- mouse 
172-1011; BIO-RAD, 
CA, USA 
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 were seeded on 6 wells plate and cultured  till the time cells got 80% 
to 90% confluent (approximately 5-7 days). Cell were kept in RIPA lysis buffer 
containing 50 mM Tris-HCl [pH 8.0], 150 mM Sodium Chloride, 1.0% Triton X-100, 
0.5% Sodium Deoxycholate, 0.1% Sodium Dodecyl Sulphate [SDS] and 1X EDTA-
free complete Protease Inhibitor cocktail for 30 minutes. The cells were scraped, 
centrifuged and the supernatant was collected. Supernatants were then boiled for 5 
minutes at 90°C, electrophoresed on 12% SDS-polyacrylamide gel and transferred 
onto PVDF membrane. The membrane was blocked for 1 hour with 5% non-fat dry 
milk in phosphate-buffered saline with tween (0.1% Tween 20) [PBST] and probed 
with the primary antibody (1:1000) (Table 10) overnight at 4  °C. Blots were then 
incubated with peroxidase-conjugated secondary antibody (1:5000) (Table 10) for 1 
hour at RT, and were developed by enhanced chemiluminescence (Pierce).  
 
 
2.5.3.4 Telomere Length Assay (TLA) 
 
TLA assay was done to analyse the ability  to grow of hESCs-Kert
ACC
. TLA was done 
using Telo TAGGG telomere Length Assay Kit (Cat # 12 209 136 001, Roche) 
according to the manufacturer’s instruction. Briefly, DNA was extracted and digested 
by using optimized mixture of frequently cutting enzyme. DNA digestion was 
followed by separation of DNA fragments by gel electrophoresis and transferred onto 
the nylon membrane for Southern blotting.  The blotted DNA fragments were 
hybridized by digoxigenin (DIG)-labeled probe specific for telomeric repeats. The 
average Telomere length was analysed by comparing the location of the telomere on 
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2.6 hESCs-Kert as a research model for the study of immune 
response in the presence of P. gingivalis (Phase 2) 
 
 
2.6.1 Study design  
 
In this phase of the study, four experimental groups were made for each cell lines 
(HaCaT and hESCs-Kert
ACC
 passage 5) to investigate modulation of specific genes by 
the following treatments. Before the start of experiment, all in vitro conditions were 
standardized. Monolayer of cells was used, initial seeding density was 1x10
5
 cells/ ml 
and experiment was started 4 days after cells seeding 
(i)  No Exposure.  
(ii) Cells were exposed to heat-killed P. gingivalis for 24 hours.  
(iii) Cells were exposed to heat-killed P. gingivalis for 48 hours.  
(iv) Cells were exposed to heat-killed P. gingivalis for 72 hours. 
 
2.6.2 Characterization of hESCs-Kert and HaCaT in physiological and 
pathological conditions 
 
2.6.2.1 Reverse transcriptase PCR (RT-PCR) and real-time RT-PCR 
analysis 
 
As described in  2.3.1.1 and  2.5.3.1 
 
2.6.2.2 Secreted alkaline phosphatase (SEAP) assay 
 
The pNFκB-SEAP reporter vector was purchased from Clontech. This vector 
possesses κB sites fused to secreted alkaline phosphatase (SEAP). Upon activation of 
cellular NFκB pathway, NFκB will bind to the κB sites and activate the expression of 
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SEAP. Cells were cultured at the density of 1x10
5
 cells/ml for 3 days to form a 
monolayer. Cells were then transfected with Fugene HD (Promega) on day 4. 
Transfection was carried out in a 6-well tissue culture plate according to the 
manufacturer’s instructions. Cell stimulation experiments were performed 24 hours 
(day 5) after transfection. The culture medium was changed to remove the 
accumulated SEAP prior to treatment of cells with heat-killed P. gingivalis. The cells 
were treated for the indicated time points after which the culture medium was 
collected and subjected to SEAP activity assays. The SEAP activity in the culture 
medium was measured with a Phospha-Light assay kit (Life Technologies), according 
to manufacturer’s instructions. 
 
2.7 Tissue Engineering of hESCs-MLE and functionality testing 
(Phase 3) 
2.7.1 Construction of hESCs-MLE model  
 
In this phase of my study,  I constructed an in vitro model from hESCs-Kert by 
keeping it at air-liquid interference. hESCs-Kert culture were grown in DSFM. The 
cultures were incubated at 37ºC in a humidified atmosphere containing 5% CO2. For 





polycarbonate culture inserts (0.63 cm diameter) with 0.4 µm diameter pore size 
(Millipore) in EpiLife medium (150 µl) (Cascade Biologics) containing human 
keratinocyte growth supplement (HKGS; 0.2% bovine pituitary extract, 5 µg/ml 
bovine insulin, 0.18 µg/ml hydrocortisone, 5 µg/ml bovine transferrin, 0.2 ng/ml 
human recombinant epidermal growth factor) and 1.5mM of calcium concentration. 
The EpiLife medium was chosen for its higher efficiency in promoting the 
proliferation of keratinocytes, while DSFM was retained for the primary culture. The 
inserts were then received 0.5 ml of medium and placed in six-well multi-plates 
(Becton-Dickinson) containing 2.5 ml of the same medium. After 48 hours of 
incubation at 37ºC in a humidified atmosphere containing 5% CO2, the EpiLife 
medium in insert and six-well plates was replaced by 1.5 ml of the EpiLife medium 
containing HKGS, 1.5 mM calcium, and 50 µg/ml AA. After 2 days of incubation, 
the cells were exposed to the air-liquid interface by removing the culture medium in 
the upper compartment of the insert. In multi-well fresh 1.5 ml of the EpiLife 
medium containing human keratinocyte growth suppliments (HKGS), 1.5 mM 
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calcium, and 50 µg/ml AA was then added to feed the keratinocytes from the bottom 
of the polycarbonate filter.   





 were mixed in 50 µg/ml of human Collagen Type I matrix and seeded on 
polycarbonate culture inserts (Dermal compartment).  Upper chamber (insert) and 
lower chamber (plate) received 0.5 ml and 2.5 ml of FAD medium (F12 and 
Dulbecco Medium) respectively and kept for 2 days as previously reported (Guenou 





 of hESCs-Kert were seeded over dermal matrix and kept in 0.5 ml of FAD 
medium for next 2 day. After 2 days,   FAD medium in upper and lower chambers 
was replaced by high calcium FAD medium supplemented with 1.5 mM calcium and 
incubated for next 2 days. After 48 hours FAD medium was removed from the upper 
chamber and cells were exposed to the air-liquid interface.    
The medium was changed every 2 days and keratinocytes were cultured for another 
14 days in order to obtain stratified cultures with characteristics of the epidermis or 
keratinized epithelium  with or without dermal compartment which I termed as  
‘‘multilayer epithelium’’ (MLE) with dermal compartment ‘‘multilayer epithelium’’ 
(MLE) without dermal compartment respectively. 
2.7.2 Characterization of MLE 
 
2.7.2.1 Hematoxylin and Eosin Staining  
 
Hematoxylin and Eosin staining was done to confirm the construction of cornified 
multilayer epithelium. Hematoxylin and Eosin staining was done as previously 
reported (Fu et al. 2010). Briefly, samples were fixed with 4% formalin for 2 hours 
followed processing of tissue in an automatic tissue processor (CITADEL 2000). For 
tissue processing, tissue following processing program was used 
- Step 1: Dehydration in 70% Alcohol for 1.5 hours  
-  Step 2: Dehydration in 95% Alcohol for 1.5 hours  
- Step 3: Dehydration in 100% Alcohol for 2 hours  
- Step 4: Clearing  in Xylene for 1 hours 
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- Step 5: Clearing  in Xylene for 1 hours 
- Step 6: Clearing  in Xylene for 1 hours 
- Step 7: Infiltration in paraffin wax  for 3 hours 
- Step 8: Infiltration in paraffin wax  for 3 hours 
 
Tissue processing was followed by impregnation of samples with wax. Samples were 
kept in paraffin wax at 54-60°C till the time of blocking. For blocking, samples were 
kept in a mould followed by pouring of melted wax and were allowed to solidify. 
Once wax got solidified then samples were immersed in chilled water. Blocking was 
followed by cutting of samples with ultramicrotome at the thickness of 5µm. Samples 
were deparaffinize in three chambers of Xylene (I and II and III) for 5 minutes each. 
Deparaffinization was followed by rehydration of the sample with ethanol with the 
descending concentrations (100% for 10 minutes, 95% for 10 minutes, 70% for 10 
minutes). Samples were then rinsed with water for 5 minutes. After rinsing, samples 
were stained with Hematoxylin for 5 minutes, followed by rinsing in running water. 
Samples were dipped in acid alcohol for one second for de-colorization, followed by 
counter staining of samples with Eosin for 5 minutes. Samples were dehydrated with 
ascending concentration of ethanol (95% for 10 minutes, 4 changes of 100% for `10 
minutes each). Dehydration was followed by 3 washes of each sample with xylene. 
Samples were viewed in light microscope (Olympus IX70). 
After the construction of hESCs-MLE, hESCs-MLE was characterized at mRNA and 
protein level. Moreover, the rationale for all experiment mentioned below was to 
analyse proteins expressed by superficial layers which play vital role in permeability 
2.7.2.2 Confocal Microscopy staining  
 
Samples were cut at 5µm of thickness and collected on the glass slide. Staining was 
done as described in section 2.4.1.1. 
 
2.7.2.3 Western blot staining 
  
As described in section 2.5.3.3 




2.7.2.4 Scanning electron microscopy  
 
As described in section 2.4.1.2 
 
2.7.3 Measurement of permeability 
 
After characterization of hESCs-MLE, it was necessary to test the functionality of 
hESCs-MLE. Therefore, for functionality testing, I used permeagear machine for 
testing permeability using the continuous flow principle as previously reported 
(Squier et al. 1991).  This permits automatic sampling of a number of replicate 
preparations, which greatly increases precision with which frequent samples can be 
obtained and can accommodate tissue specimens as small as 4 mm in diameter 
Disks of the cultured tissue between 5 and 10mm in diameter were mounted between 
the upper and lower halves of the perfusion chambers. The chambers were then 
mounted in thermo-stated holders so physiological temperature (37⁰C) can be 
maintained.  A solution containing potential permeates was pipetted into the upper 
donor chamber, which had a volume of 2 ml. PBS was pumped through the lower 
receptor chamber (0.3 ml total volume) at a rate of 1ml per hour by means of a 
peristaltic pump.  Fractions were collected from each chamber at 30 min intervals by 
means of an automated fraction collector. The collected receptor and donor fluids 
were mixed with scintillation fluid and the radioactivity was determined using a 
liquid scintillation counter equipped with automatic quench compensation so as to 
achieve a 2 seconds level of 2%. The concentration of penetrant in the donor and 
receptor fluids for each time point were determined, and the flux was determined as 
the amount of penetrant moving across the tissue per unit time and area. This was 
expressed as  (dpm)/cm
2
 /min. (DPM: diffusion per minute).  
Flux values at each sampling interval were plotted against time until there was no 
increase in value i.e. the compound was then assumed to had reached a steady state 
for that tissue, and 2-3 subsequent readings were then taken from which to calculate 
the mean value for each chamber.  Generally, 3 replicate perfusion chambers were set 
up and sampled at the same time, and a mean flux value and a measure of dispersion 
were calculated. A permeability constant (Kp) were calculated from the relationship: 
Materials and Methods 
51 
 
Kp =  J/ΔC ( J is the flux at steady state, and ΔC was the average concentration 
gradient expressed in cpm/cm
3 
) as previously described  (Niessen et al. 1999).  The 
units of Kp were cm/min. The use of a Kp allow results to be compared with those of 
other investigators using different tissues under different conditions. 
 
2.8 Statistical Analysis 
 
 For statistical analysis, one-way ANOVA post-hoc tests (Tukey and Bonferroni) and 
























3 Results  
3.1 Phase 1: hESCs differentiation into clinically compliant 
hESCs-Kert 
3.1.1 Characterization of hESCs-ebF 
3.1.1.1  Characterization of hESCs-ebF at mRNA level 
 
The hESCs-ebF morphology was similar to typical fibroblast. Cells were found to be 
elongated (Figure 2). hESCs-ebF were grown and characterized for 10 passages. The 
expression of the pluripotency marker Oct4 was observed from passage 1 to 4 on RT-
PCR (Figure 3). Therefore, it is likely that hESCs-ebF at passages 1 to 4 were not 
fully differentiated and were inappropriate for the construction of the ACC system. 
However, hESCs-ebF at passage 5 to 10 were further characterized for the expression 
of Vimentin and Prolyl 4-hydroxylase to confirm their fibroblastic lineage (Figure 4). 
I observed the expression of Vimentin and Prolyl 4-hydroxylase in hESCs-ebF from 
passage 5 onwards. 
 
Figure 2: (a-c) Phase contract images of different stages of derivation of hESCs-ebF.  (a) hESCs were 
kept on mitotically inactivated mouse feeder cells in undifferentiated state. (b) Seeding of embryoid 
bodies on gelatin-coated plates. hESCs-ebF were found to be differentiated from the periphery of the 
embryoid bodies. (c) hESCs-ebF at passage 2 showing fibroblast-like morphology (a-c). Scale bar = 






Figure 3: Characterization of hESCs-ebF. Expression of pluripotency marker (Oct 4). ß-Actin was taken 




Figure 4: Characterization of hESCs-ebF. Expression of fibroblast markers Vimentin and  Prolyl 4-
hydroxylase. ß-Actin was taken as the loading control. Abbreviationss: P, Passages of hESCs-ebF;  























3.1.1.2 Characterization of hESCs-ebF at protein level 
 
For the characterization of hESCs-ebF at protein level, the expression of KGF-I was 
analysed by ELISA from passage 5 to 10 of hESCs-ebF.  The level of KGF-I was 
found to be highest in hESCs-ebF-passage 8  (Figure 5). Interestingly, KGF-I 
expression was found to be reduced in passage 9  and passage 10  of hESCs-ebF.  
hESCs-ebF P8 was further characterized for Fibronectin expression (Figure 6). 
Correspondingly, I found no expression of epithelial precursor marker K18 and/or 
epidermal marker K14 in hESCs-ebF P8 (Figure 6b and Figure 7a).  
 
 
Figure 5: Characterization of hESCs-ebF at protein level (ELISA).Results of ELISA showing the KGF I 
secretion by hESCs-ebF at P5- P10. Error bars indicate the mean +/- SEM (n=3). *= p< .05 vs. all 



























Figure 6: Characterization of hESCs-ebF passage 8 (Immunofluorescence staining). 
Immunofluorescence staining (primary antibody, 1:100; secondary antibody, 1:100) showing the 
expression of (a) DAPI, (b) K18 (D-10), (c) Fibronectin (H-300) and (d) Merged by hESCs-ebF passage 
8 (Scale bar = 100µm) and  (e) K18 (D-10) and DAPI by hESCs-Kert at day 10 on Matrigel system. 
Abbreviations: hESCs, human embryonic stem cells; hESCs-ebF, human embryonic stem cells derived 





a                                      hESCs-ebF b                                      hESCs-ebF 
d                                      hESCs-ebF c                                        hESCs-ebF 
e                         hESCs-Kert – day 10 








Figure 7: Characterization of hESCs-ebF passage 8. (Phase contrast and Immunofluorescence staining). 
Phase contrast and immunofluorescence staining (primary antibody, 1:100; secondary antibody, 1:100) 
showing the expression of (a) DAPI, (b)  K14 (LL002), (c) K14 (LL002) and DAPI, (d)  Phase contrast, 
K14 (LL002) and DAPI (merged)  of  HaCaT cells-hESCs-ebF P 8 in co-culture. (Scale bar = 50µm). 
Abbreviations: H, hESCs-ebF; K, HaCaT cells. 
 
3.1.2 Establishment of the ACC system and medium optimization  
 
For the establishment of the ACC system, hESCs were co-cultured with mitotically 
inactivated hESCs-ebF passage 8. hESCs and hESCs-ebF required different culture 
conditions. Therefore it was necessary to optimize the culture milieu suitable for both 
cells types. The ACC system was kept in three different medium conditions for 5 
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and hESCs medium without FGF-2: human embryonic stem cells medium). Viability 
of co-cultured cells was tested by MTS-cell viability assay. Viability assay results 
showed that only FAD medium and ES Medium were able to support the ACC 
system with no significant difference in cell viability between them. Correspondingly, 
I found significantly less viable cells in the ACC system kept in DSFM compared to 
other groups (Figure 8). Thus I selected FAD medium for keratinocyte differentiation 
in the autogeneic co-culture system (ACC system).  
 
 
Figure 8: Optimization of in vitro conditions. MTS assay results showing the cell viability in the ACC 
system in different medium conditions at day 5. Error bars indicate the mean +/- SEM (n=3); * = p< .05 
vs. ‘DSFM’ Sample. Abbreviations: FAD, F12 and DMEM medium; DSFM, Defined Serum Free 


































3.1.3 Effect of Retinoic Acid (RA) in induction of hESCs differentiation into 
keratinocyte lineage in the ACC system 
 
After optimization of in vitro conditions, it was required to drive hESCs into 
keratinocyte lineage. Previously, Metallo et al. reported that early application of RA 
drives hESCs into relatively pure population of keratinocyte (Metallo et al. 2008). 
However, RA has never been used in autogeneic co-culture system (ACC). Therefore, 
it was of my interest to optimize the dose and temporal effect of RA.    
3.1.3.1 Dose optimization of RA  
 
For dose optimization of retinoic acid, three different concentrations (0.1µM, 0.5µM 
and 1µM) were applied. Results of flow cytometry showed that application of 0.5µM 
of RA induces significantly higher p63 (+) cells compared to other concentrations of 
RA in the ACC system. Additionally, neural progenitor marker nestin was found to 
be increased simultaneously (Figure 9).  
 
Figure 9: Optimization of in vitro conditions. Flow cytometric analysis showing the effect of different 
concentration of RA at day 10 in ACC system. Cells without staining were taken as control for 

























3.1.3.2 Optimization of temporal effect of RA 
 
To analyse the temporal effect of RA, the ACC system was treated with 0.5µM of RA 
until day 10, day 15 and day 20 respectively (Figure 10a). I found continuous 
expression of keratinocyte and neural markers (pax6 and sox1). This result led me to 
analyse the trend of neural and keratinocyte markers through real time RT-PCT. 
Therefore, I selected two extreme time points i.e. day 10 and day 20.  Results of real 
time RT-PCR showed that the continuous exposure treatment for 20 days resulted in 
higher expression of p63. However, I also found a significant increase in the 
expression of neural markers (pax6 and sox1) (Figure 10b). As the increasing trend of 
neural markers along with keratinocyte marker was found at day 20, therefore, 





Optimization of in 
vitro conditions. (a)  
Qualitative analysis 
showing the 
temporal effect of 
0.5 µM RA at 
different time points. 
(b) Real time RT-
PCR results showing 
the temporal effect 
of 0.5 µM of RA. 
Error bars indicate 
the mean +/- SEM 
(n=3); * = p< .05 vs. 










































3.1.4 Effect of Activin in keratinocyte differentiation in the ACC system 
 
Early application of RA resulted in hESCs differentiation into keratinocyte lineage. 
However, I also found higher contamination of neural lineage. Therefore, I aimed to 
inhibit neural lineage to obtain the pure population of keratinocyte. Application of 
Activin in the presence of RA in autogeneic co-culture system has not been reported 
yet. Therefore, I optimized the temporal and dose effect of Activin.  
 
3.1.4.1 Optimization of temporal effect of Activin  
 
To analyse the temporal effect, Activin was applied for 3 days at different time points 
(day 1- day 11) of differentiation. Activin was applied for 3 days at different time 
points. Moreover, the application of Activin was kept for 3 days because previously 
Coraux et al. and Aberdam have reported to use BMP-4 for 3 days only for the 
inhibition of neural pathways while inducing keratinocyte differentiation (Coraux et 
al.2003; Aberdam 2004). I found the temporal effects of Activin when applied at 
different time points (Figure 11; Figure 12). The early application of Activin at day 1 
and day 2 inhibited the neuro-ectodermal differentiation of hESCs by maintaining the 
cells in a pluripotent state. Interestingly, I found that application of Activin at day 3, 
day 4, day 5, day 6, day 7 and day 8 synergized neuro-ectodermal differentiations, 
predominantly the neural differentiation with the expression of sox1. However the 
introduction of Activin at day 9, day 10 and day 11 augmented the keratinocyte 
differentiation while inhibiting the neural differentiation effect of RA (Figure 11). For 
more quantitative analysis, real time RT-PCR was performed of the same samples 
and I found the similar trend (Figure 12). Moreover, the application of Activin at day 






Figure 11: Temporal effect of Activin in keratinocyte differentiation. Qualitative analysis showing the 
temporal effect of Activin on hESCs differentiation towards the neuroectodermal lineage in ACC system 
at day 15. Experiment was done in triplicate.  ß-Actin was taken as a loading control.  Abbreviations: ß-












Figure 12: Effect of Activin in keratinocyte differentiation. Results of real time RT-PCR showing the 
temporal effect of Activin on hESCs differentiation towards the neuroectodermal lineage in ACC system 
at day 15.  ß-Actin was taken as a reference gene.  Error bars indicate the mean +/- SEM (n=3); * = p< 








3.1.4.2 Dose optimization of Activin  
 
Alternatively, I found no substantial difference within different concentrations 
(10ng/ml, 25ng/ml, and 50ng/ml) of Activin when applied at the optimized time 
point. Over all I found higher expression of early keratinocyte markers (K18 and 
ΔNp63) and lower expression of neural specific markers (sox1, pax6 and β-Tubulin) 
(Figure 13). Thus, I was able to get approximately 85% ± 4.5(SE) of p63 (+) cells 
from hESCs at day 20 when treated with 0.5µM of RAs for 20 days and 25ng/ml of 





Figure 13: Dose 










lineage in ACC 
system at day 12.  ß-
Actin was taken as a 
loading control.  
Abbreviations: ß-Act, 
ß-Actin; RA, 



























Figure 14: Effect of Activin in keratinocyte differentiation. Flow cytometric analysis showing the effect 
of Activin in the presence of RA on the keratinocyte differentiation of hESCs at day 20 in ACC system. 
Abbreviations: ß-Act, ß-Actin; RA, Retinoic Acid.  
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3.1.5.1 Characterization of hESCs-KertACC in ACC system at mRNA 
 
After optimization of the in vitro condition, hESCs were differentiated to 





characterized at different time points (Figure 15a; Figure 15b). I observed the higher 
expression of primitive epithelial marker K18 until day 20 from the start of 
differentiation and then found it to decrease at later time point (Figure 15b). 
Concurrently, epidermal precursor marker p63 and the basal keratinocyte marker of 
stratified epidermis, K14 were found to increase steadily with time (Figure 15a; 
Figure 15b). In addition, there was progressive reduction of neural markers (sox1, 











Figure 15: Characterization of hESCs-KertACC at mRNA level. (a): Qualitative analysis showing kinetics 
of expression of keratinocyte markers. (b): Quantitative analysis showing the kinetics of expression of 
keratinocyte, neural and pluripotency markers at different time points. Error bars = mean +/- SEM (n=3); 












 at protein level was done to confirm their 
keratinocyte lineage (Figure 16a; Fig 16b and Figure 16c). hESCs-Kert
ACC
 were able 
to undergo terminal differentiation and expressed suprabasal keratinocyte markers 
such as Involucrin and Filaggrin in DSFM supplemented with 1.5 mmole/L of 
calcium chloride (Fig 16d). These results suggest that hESCs-Kert possess 
characteristics of epidermal differentiating keratinocytes.  
 
Fig 16: Characterization of hESCs-Kert
ACC 


































Fig 16: Characterization of hESCs-Kert
ACC 
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Fig 16: Characterization of hESCs-Kert
ACC 











Figure 16: Characterization of hESCs-KertACC at protein level.  (a): SDS-polyacrylamide  gel 
electrophoresis, (b) flow cytometric analysis and (c, d) immunofluorescence staining. (a): SDS-
polyacrylamide gel electrophoresis showing the expression of K14 protein by hESCs-Kert in ACC 
system at day 30. (b): Flow cytometric analysis of hESCs-Kert showing the percentage of K14 (+) cells 
at day 30.  (c, d): Immunocytochemistry of hESCs-Kert (passage 5) and HaCaT cell (positive control) 
for (c): Integrin α6 (3H1512), K14(LL002) and K18 (DC-10) (primary antibody, 1:100; secondary 
antibody, 1:100) (d): epidermal terminal differentiation markers (Involucrin (green) (SY-5) and  
Filaggrin (red) (H-300) (Scale bar = 100µm)  in stratified area in high Ca2+ medium.   Abbreviations: 


















3.1.5.3 Characterization of different passages of hESCs-KertACC   
 
I found that hESCs-Kert
ACC 
 were able maintain the high percentage of K14 (+) cells 
in serum-free medium (Figure 17a). Moreover, hESCs-Kert
ACC 
were able to propagate 
for 10 passages without reaching the Hayflick limit (Figure 17b). However, I found 
the progressive shorting of telomere length and Telomerase Reverse Transcriptase 
(TERT) expression with the increasing passage numbers (Fig 17c; Fig 17d).  



































































































































Figure 17: Characterization of different passages of hESCs-KertACC (a) Histogram gram, (b) cell count, 
(c) telomere length and (d) TERT expression. (a) Flow cytometry data showing the percentage of K14 
(+) cells in different passages of hESCs-Kert using the flow cytometric analysis. Sample with isotype-
specific or no primary antibody was taken as a control. (b): The cell count numbers of different passages 
of hESCs-Kert. (c, d): Quantitative analysis of (c) Telomere length; (d): TERT expression. (b, d): Error 
Bars = mean +/- SEM (n=3); (b) * = p< .05 vs. ‘0 hour’ Sample; (d) * = p< .05   vs. ‘hESCs’ Sample. 
(c) Each bar represents the mean value of a single sample analysed in triplicate.  Abbreviations: HaCaT 
cells, Human Keratinocyte immortalized cell line; hESCs, human embryonic stem cells; hESCs-Kert, 
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3.1.5.4 Analysis of xenogeneic contamination in hESCs-Kert 
 
For clinical application of hESCs-Kert
ACC
, it was important to analyse the xenogeneic 
contamination. Therefore, mouse major histocompatibility complex type I and type II 
were analysed. I found no mEF contamination in hESCs-Kert
ACC














Figure 18: Flow cytometric analysis of xenogeneic contamination of hESCs-KertACC. Representative 
flow cytometric analysis of mouse MHC I and MHC II by hESCs-KertACC passage 5. Abbreviations: 






































3.1.6 Establishment of the serum-free, feeder-free AFF system for 
keratinocyte differentiation 
3.1.6.1 Characterization of ECM from hESCs-ebF 
 
The exposure of hESCs-ebF to crowding molecules alone resulted in the extraction of 
ECM substrate containing laminin but no collagen type IV (Figure 19a). 
Alternatively, hESCs-ebF were able to secrete collagen type IV in ECM substrate 
when exposed to crowding medium supplemented with Activin for 3-5 days (Figure 
19b). Additionally, the application of Activin also found to enhance the overall ECM 




















Figure 19: Characterization of the AFF system in the presence of crowders supplemented with or 
without Activin. (a): Confocal Microscopy images showing the expression of Collagen Type IV (COL-
94) and Laminin (primary antibody, 1:100; secondary antibody, 1:100) in the absence of Activin. (b): 
Confocal Microscopy images showing the expression of Collagen Type IV and Laminin in the presence 
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Figure 20: Characterization of the AFF system in the presence of crowders supplemented with or 
without Activin (SEM Images). (a): SEM images of extracted ECM in the absence of Activin. (b): SEM 
images of extracted ECM in the presence of Activin. Abbreviations: ECM, extracellular matrix. 
 







 differentiated in AFF system were characterized at mRNA and protein 
level.  




system followed the same kinetics of keratinocyte marker expression 
as hESCs-Kert
ACC 




Figure 21: Characterization of 
hESCs-Kert differentiated in 
AFF system at mRNA level. 
Qualitative analysis of kinetic of 
expression of keratinocyte 
markers. ß-Actin is the 
housekeeping gene. 
Abbreviations: β-Act, β Actin; 



























Figure 22: Characterization of hESCs-KertAFF at mRNA level. Quantitative analysis of kinetics of 
expression of keratinocyte markers. Error bars = mean +/- SEM (n=3); * = p< .05 vs. ‘hESCs’ Sample.  
Abbreviations: D, day 10. 
   
3.1.7.2 Characterization of hESCs-KertAFF at protein level 
 
I was able to get 89% ± 5.1 (SEM) of K14 (+) by day 30 from the start of 
differentiation (Figure 23). Additionally, the immunofluorescence staining of hESCs-
Kert
AFF 
showed strong expression of K14 and alpha integrin-6 by majority of the 
cells. Concurrently, I found that K18 was expressed by very few hESCs-Kert
AFF
 
(Figure 24).  hESCs-Kert
AFF
 were able to grow until passage 7.  
   
Figure 23: Characterization of the hESCs-
KertAFF at protein level (Flow cytometric 
analysis). Flow cytometric analysis showing 
the K14 (+) cells at Day 30. Abbreviations: 
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Figure 24: Characterization of the hESCs-KertAFF at protein level. Immunofluorescence staining of 
hESCs-KertAFF at Passage 5 for K14 (LL002) and K18 (DC-10), Integrin α6 (3H1512) (primary 
antibody, 1:100; secondary antibody, 1:100). Abbreviations: D, Day; K, Keratin; hESCs-KertAFF, hESCs 
derived keratinocyte in autogeneic feeder free system. 
 
3.1.7.3 hESCs-Kert differentiated on AFF system vs. hESCs-Kert 
differentiated in Matrigel system 
 
I found that the AFF system was as efficient as the xenogeneic mouse sarcoma 
derived extracellular matrix (Matrigel system) for keratinocyte differentiation (Figure 
25). I found no significant difference between the two systems at day 10.  
 
Figure 25: Comparison of efficiency of AFF with 
the Matrigel system.  Gene expression of p63 and 
K18 by hESCs-derived keratinocyte progenitors in 
AFF and Matrigel systems at day 10. 
Abbreviations: AFF, Autogeneic feeder free 
system; K, Keratin. 
 
 












3.2 Phase 2: hESCs-Kert as an alternative research model for the 
study of immune response 
 
 
3.2.1 Expression of TLRs and cytokines in hESCs-Kert and HaCaT under 
normal conditions 
 
TLRs play a vital role in innate immunity and responsible for activation of many 
downstream pathway when exposed to any pathological environment (Akira et al. 
2001). For more understanding of hESCs-Kert expression of different cytokines and 
TLRs under normal culture milieu, I analysed the mRNA expression of TLR-2, TLR-
4, TLR-5, TLR-9, IL-6, IL-8, and TNF -α and iNOS by RT-PCR (Figure 26). My 
results showed the expression of TLR-2, TLR-4, IL-6, IL-8 and TNF-α in HaCaT and 
hESCs-Kert at mRNA level (Figure. 26). Additionally, TLR-9 was not found to be 
expressed in both cell types. Alternatively, I found the expression of inducible nitric 








Figure 26:  Analysis of Toll-like receptors expression kinetics by hESCs-Kert and HaCaT in the absence 
of P. gingivalis. Abbreviations:  HaCaT, human keratinocyte immortalized cell line; hESCs-Kert, hESCs 










3.2.2 Expression of TLRs and cytokines in hESCs-Kert and HaCaT stimulated 
with P. gingivalis 
To mimic the pathological condition, I used heat killed P. gingivalis, a common non-
motile, gram negative bacteria, containing LPS as a major component in their cell 
wall (Naito et al.2008) and analyse the respond of hESCs derived research model. P. 
gingivalis resides in dental plaque present proximal to sulcular gingival keratinocytes 
and up-regulates the pro-inflammatory cytokines which contribute to inflammation in 
periodontitis (Giacaman et al. 2009). Therefore, the possible effects of P. gingivalis 
on HaCaT and hESCs-Kert were quantified at mRNA level (Figure 27). Additionally, 
the kinetics of gene expression of TLR-2, TLR-4, IL-6, IL-8, iNOS and TNF-α at 24, 
48, and 72 hours following P. gingivalis treatment in hESCs-Kert were compared 
with HaCaT (Figure 27). I found the similar kinetics of gene expression of IL-8, IL-6, 
and TNF-α and TLR-4 in both cell types. HaCaT and hESCs -Kert incubated with P. 
gingivalis for 72 hours showed 7.5 (SEM±0.12) and 7 (SEM±0.11) folds higher 
relative expression of IL-8 compared to their respective controls. Similarly, exposure 
of HaCaT and hESCs-Kert to P. gingivalis resulted in progressive increase in TNF-α 
gene expression in both cell types. I found 5.1 (SEM±0.23) and 5.4 (SEM±0.3) folds 
higher expression of TNF-α at 72 hours following treatment with P. gingivalis 
compared to the control samples in HaCaT and hESCs-Kert respectively. 
Alternatively, P. gingivalis exposure for 72 hours resulted in no significant increase 
in IL-6 relative gene expression in both cell types analysed. However, an increasing 
trend was observed in both research models and I found around 1.5 folds higher 
expression of IL-6 by both cells types after 72 hours of P. gingivalis treatment. 
Interestingly, exposure to P. gingivalis for 24 hours resulted in significant increase in 
TLR-4 gene expression in both cell types. HaCaT showed 3.7 (SEM±0.12) and 
hESCs-Kert showed 2.4 (SEM±0.2) folds higher TLR-4 relative gene expression 
compared to the controls respectively at 24 hours. However, the expression of TLR-4 
declined at later time point following prolonged P. gingivalis exposure in both 
research models. 
Surprisingly, I did not find the similar kinetics in the gene expression of TLR-2 in 
both cell types. HaCaT showed the highest expression at 24 hours of P. gingivalis 
exposure i.e. 2.56 (SEM±0.1) folds induction compared to the control.  Additionally, 
I did not find significant increase in TLR-2 gene expression with the prolonged P. 
gingivalis exposure. In contrast, hESCs-Kert showed the maximum expression (2.7 
(SEM±0.22) fold higher expression compared to respective control) at 48 hours of 




TLR-2 gene expression after 48 hours of P. gingivalis exposure. Nevertheless, I 
found that the P. gingivalis treatment resulted in overall significant increase in TLR-2 
expression in both research models compared to their respective controls. Kinetics of 
iNOS gene expression in the presence of P. gingivalis was found to be different in 
both cell lines. iNOS gene expression was found to increased progressively in hESCs-
Kert with the maximum expression of 2.92 (SEM±0.2) relative gene expression 
compared to the control at 72 hours after P. gingivalis exposure.  Alternatively, 
HaCaT did not show any significant increase in iNOS expression at any time point of 







Figure 27: Analysis of kinetics of gene expression of TLRs and cytokines by hESCs-Kert and HaCaT 
cells in the presence and/or absence of P. gingivalis.  Error bars = mean +/- SEM (n=3); * = p< .05 vs. 
‘No Treatment’ Sample. Abbreviations: h, hours of heat killed P, gingivalis treatment to cells; No 


















3.2.3 Activation of NFĸB in H9-Kert and HaCaT when exposed to P. gingivalis 
 
The activation of the NFĸB signaling pathway in HaCaT and hESCs-Kert following 
P. gingivalis treatment was determined. Treatment of HaCaT and hESCs-Kert with P. 
gingivalis resulted in a significant up-regulation of cellular NFĸB. NFκB activation 
peaked at 72 hours following P. gingivalis stimulation in both cell types. However, 
the magnitude of NFĸB activation in both research models did not vary significantly 

















Figure 28: SEAP assay analysis of NFĸB activation in hESCs-Kert and HaCaT when exposed to P. 
gingivalis. Activation of NFκB was analysed at different time points. Error bars = mean +/- SEM (n=3); 
* = p< .05 vs. ‘No Treatment’ Sample. Abbreviations: h, hours; HaCaT, Keratinocyte immortalized cell 












3.3 Phase 3: hESCs-MLE: permeability testing model for 
industrial application 
 
3.3.1 Construction of hESCs-MLE  
 
hESCs-Kert were able to form MLE when kept at air liquid interface for 14 days 
(Figure 29, Figure 30). H&E staining results showed 4-5 layered MLE derived from 
hESCs (Figure 29 and Figure 30a) and control cell line (Figure 30b). Although the 
cell orientation was not similar as human oral mucosa or skin in vivo, however, I 
found the similar pattern in hESCs-derived MLE compared to control cell lines 
derived MLE in vitro. I also found the progressive flattening of cells while moving 
from the bottom layer to the superficial layer followed by the total loss of nucleus 
with full cornified at the superficial layer. Further characterizations were required 
therefore I did a detailed characterization hESCs-MLE at mRNA and protein level.  
 
 
Figure 29:  Construction of hESCs derived multilayer epithelium (hESCs-MLE) (H&E staining).H& E 
staining was done at different time points of hESCs-MLE construction. All images were reproduced at 













Figure 30: Characterization of MLE at histological level; stained with H&E staining and reproduce at 
the same magnification (100x). (a) H&E staining of hESCs-Kert derived MLE at day 14. 
Abbreviationss: hESCs, human embryonic stem cells; Control, HaCaT derived multilayer epithelium (b) 

















3.3.2 Characterization of hESCs-MLE at mRNA level 
 
MLE derived from hESCs-Kert and HaCaT were characterized at mRNA to analyse 
the expression of terminally differentiated keratinocyte markers. I found the similar 
expression of K1, K76, K4, K9, K10, K13, K17, Involucrin, Filaggrin and K16 in 
MLE derived from both cells lines. Additionally, monolayer of hESCs-Kert and 





















Figure 31: Characterization of MLE at mRNA level.  Expression of terminally differentiated 
keratinocyte markers. ß-Actin was taken as loading control. Abbreviations: β Act, β Actin; HaCaT, 
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3.3.3 Characterization of hESCs derived MLE at Protein level   
 
3.3.3.1 Confocal Microscopy  
 
hESCs-MLE was characterized at protein level. Confocal microscopy results showed 
the strong expression of Involucrin and Filaggrin at the superficial membrane of MLE 
derived from hESCs (Figure 32a-d) and HaCaT (Figure 32e). Moreover, I found a 
strong expression of K14 at basal layer of hESCs (Figure 33 b and c) and HaCaT 
(Figure 33d) derived MLE. Additionally, I found the progressive loss of K14 













Figure 32: Confocal microscopy for Involucrin and Filaggrin expression (primary antibody, 1:100; 
secondary antibody, 1:100) by hESCs-MLE (a-d) and (e) HaCaT derived MLE. hESCs-MLE expression 
for (a) DAPI, (b) Involucrin (SY-5), (c) Filaggrin (H-300) and (d) Merged. (e): merged image of 
Involucrin (SY-5), Filaggrin (H-300) and DAPI of HaCaT –MLE at day 14. Magnification = 100x. 
Abbreviationss: MLE: multilayer epithelium; hESCs, human embryonic stem cells; hESCs-ebF, Human 










Figure 33: Confocal microscopy for K14 expression (primary antibody, 1:100; secondary antibody, 
1:100) by hESCs-MLE (b-c). (d): HaCaT derived MLE. hESCs-MLE showing the expression of DAPI 
and K14 (LL002) (Merged). Images were taken on day 14 at 100x magnification. Abbreviationss: MLE: 
multilayer epithelium; hESCs, human embryonic stem cells; hESCs-MLE, human embryonic stem cells-
derived multilayer epithelium. 
 
3.3.3.2 Western Blotting  
 
hESCs- MLE was further characterized by western blotting to confirm the expression 
of  superficial surface protein i.e. Involucrin and Filaggrin. I found the expression of 
Filaggrin and Involucrin at protein similar to control. HaCaT-derived MLE and β 
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Figure 34: Characterization of hESCs-MLE. Western Blot results showing the expression of Involucrin 
(SY-5) and Filaggrin (H-300) protein by hESCs-MLE at day 14. HaCaT- MLE was taken as reference 
control. Β-Actin was taken as loading control. Abbreviationss: MLE: multilayer epithelium; hESCs, 
human embryonic stem cells; hESCs-MLE, human embryonic stem cells derived multilayer epithelium; 
Control, HaCaT-derived MLE 
 
3.3.4 Topography of superficial surface of hESCs-MLE 
 
To confirm the keratinization of hESCs-MLE, SEM analysis was done. I found the 
cornified layer (marked with the letter C) on the surface of hESCs-derived MLE 
(Figure 35a). Moreover, terminally differentiating keratinocytes beneath the cornified 
layer can be seen in Figure 33a (marked as SK) as rounded figures (Figure 35a). 
Superficial cornified layer was found to be flattened and the boundaries between 
adjacent cells. HaCaT-derived MLE was taken as control (Figure 35b). (This work 
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  Figure 35: Scan Electron Microscopy of hESCs-MLE 
(a, b). SEM images of MLE derived from hESCs (a) and 
HaCaT (b). Abbreviations: C, cornified  layer; SK, 
stratified keratinocytes. HaCaT derived keratinocyte was 
taken as control. All images in (a) are the same sample 
but different magnifications (200x and 650x). Image (b) 
was taken at 500x magnification. (a) Fractured view, (b) 






3.3.5 Permeability testing of hESCs-MLE by using labeled water   
 
After characterization of hESCs-MLE, it was required to test the functionality of 
hESCs-MLE. Permeability with the tritiated water considered as the gold standards to 
test the permeability of in vitro multilayer epithelium models. Therefore, the 
functionality of hESCs-MLE was done by analyzing the permeability. The effect of 
flow rate of 100 µL/h of tritiated water through the receptor chambers was 
determined by measuring amount of DPM (Figure 36), flux rate (Figure 37) and Kp 
(Figure 38) of hESCs-MLE with dermal compartment, hESCs-MLE without dermal 
compartment, HaCaT- MLE with dermal compartment, HaCaT-derived MLE without 
dermal compartment, insert without cells and inserts with layer of hESCs-ebF 
(dermal compartment only) were analysed.  
The Kp value (±SEM) (Figure 38) was obtained from flux flow (Figure 37) and flux 
flow was obtained from DMP values of titrated water passed through the tissues. 
Therefore, overall the trend of DPM, flux flow and Kp was found to be similar.  Plots 
of the Kp values tritiated water penetration revealed that samples ‘inserts without 
cells’ and sample ‘hESCs-ebF’ showed the maximum permeabilization. Moreover, 
their permeabilization reached to their respective lag time < 0.5 hours compared to 
other samples. Kp values for hESCs-derived MLE without dermal compartment 
(sample: hESCs-Kert) and HaCaT-derived MLE without dermal compartment 
(sample: Control Kert) were found to increase progressively. However, sample 
‘hESCs-Kert’ showed continuous flow (lag stage) at 2.5 hours from the start of the 
experiment. Alternatively, sample ‘Control Keratinocyte’ was found to reach its lag 
time at 3 hours from the start of experiment.  
Kp values for hESCs-MLE with dermal compartment (sample: hESCs-Kert/hESCs-
ebF) and HaCaT derived MLE with dermal compartment (sample: Control-
Kert/hESCs-ebF) showed similar trend and I found no significant difference between 
the their respective lag time. I found that both samples were completely 











Figure 36: Permeability testing. Graph showing the DPM values of titrated water across different 
samples. Error bars = mean +/- SEM (n=3).  Abbreviations: Time, in hours;  hESCs, human embryonic 
stem cells; hESCs-Kert, hESCs derived MLE comprising of hESCs-Kert only; hESCs-Kert/hESCs-ebF, 
hESCs derived MLE comprising of hESCs-Kert (epidermal compartment) and hESCs derived fibroblast 
(dermal compartment); Control Keratinocyte, MLE comprising of HaCaT only (control keratinocyte cell 
line); Control Kert/hESCs-ebF, MLE comprising of control cell line (epidermal compartment) and 
hESCs derived fibroblast (dermal compartment); hESCs-ebF, inserts with hESCs derived fibroblast only; 








Figure 37: Permeability testing. Graph showing the Flux values (dpm/min/cm-2) of titrated water across 
different samples. Error bars = mean +/- SEM (n=3).  Abbreviations: Time, in hours; hESCs, human 
embryonic stem cells; hESCs-Kert, hESCs derived MLE comprising of hESCs-Kert only; hESCs-
Kert/hESCs-ebF, hESCs derived MLE comprising of hESCs-Kert (epidermal compartment) and hESCs 
derived fibroblast (dermal compartment); Control Keratinocyte, MLE comprising of HaCaT only 
(control keratinocyte cell line); Control Kert/hESCs-ebF, MLE comprising of control cell line (epidermal 
compartment) and hESCs derived fibroblast (dermal compartment); hESCs-ebF, inserts with hESCs 









Figure 38: Permeability testing. Graph showing the Kp index values of titrated water across different 
samples. Error bars = mean +/- SEM (n=3).  Abbreviations: Time, in hours; Kp, permeability constant; 
hESCs, human embryonic stem cells; hESCs-Kert, hESCs derived MLE comprising of hESCs-Kert only; 
hESCs-Kert/hESCs-ebF, hESCs derived MLE comprising of hESCs-Kert (epidermal compartment) and 
hESCs derived fibroblast (dermal compartment); Control Keratinocyte, MLE comprising of HaCaT only 
(control keratinocyte cell line); Control Kert/hESCs-ebF, MLE comprising of control cell line (epidermal 
compartment) and hESCs derived fibroblast (dermal compartment); hESCs-ebF, inserts with hESCs 
derived fibroblast only; Insert without cells was taken as control.
Time points 


















4.1 Phase 1: hESCs differentiation into clinically compliant 
hESCs-Kert 
 
4.1.1 hESCs differentiation into hESCs-Kert in an ACC system  
 
4.1.1.1 Establishment of ACC system 
 
Animal-derived fibroblast has been commonly used for keratinocyte propagation and 
differentiation. Previously, the importance of fibroblasts in keratinocyte 
morphogenesis has been studied by very many researchers (Mackenzie et al.1993; el-
Ghalbzouri et al.2002). However, the role of hESCs-derived fibroblast in hESCs 
differentiation towards keratinocyte lineage has not been reported. In my study, I first 
differentiated hESCs into fibroblasts (hESCs-ebF) (Figure 2Figure 2) and propagate 
them for 10 passages. However, I found the expression of pluripotent marker Oct4 in 
four early passages of hESCs-ebF propagation (Figure 3), suggesting that these cells 
still retained some degree of pluripotency, thus making them unsuitable for the 
establishment of the ACC system.   Therefore, hESCs-ebF was further characterized 
at Passage 5-10 for their secretion of growth factors. Previously, it has been shown 
that fibroblasts are capable of secreting different growth factors such as Keratinocyte 
Growth Factor- I (KGF I) which in particular, plays an important role in keratinocyte 
morphogenesis (Fusenig et al.1994 ; Yang et al.1999). Therefore to further optimize 
conditions for keratinocyte differentiation, the expression of KGF-I was analysed 
from passage 5 to 10 of hESCs-ebF (Figure 5).  The level of KGF-I was found to be 
highest in hESCs-ebF-passage 8 (P8). To further confirm the fibroblastic lineage 
commitment, hESCs-ebF P8 was characterized for Fibronectin expression (Figure 6) 
which is normally produced by cultured fibroblasts (McKeown-Longo et al.1984). 
Moreover, the lack of expression of epithelial precursor marker K18 and/or epidermal 
marker K14 in hESCs-ebF P8 confirmed that hESCs-ebF were not from ectodermal 
lineage (Figure 7). 
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4.1.1.2 RA induces neuroepithelial differentiation from hESCs  
 
For the induction of keratinocyte differentiation I used RA as previously reported by 
Metallo et al in the feeder-free system (Metallo et al.2008). Moreover, it has been 
shown previously that RA induces p63 expression through the retinoic acid receptor 
(RAR) (Schuldiner et al.2000; Chen et al.2005). p63 is supposed to be a well-known 
marker for epidermal progenitors and an essential transcription factor for keratinocyte 
differentiation (Yang et al.1999; Mills et al.1999; McKeon 2004). However, RA has 
not been used for keratinocyte differentiation in a co-culture system. Therefore, there 
is a need for optimization of the dose and temporal application of RA. In contrast to 
the findings of Metallo et al.my flow cytometry results showed that application of 
0.5µM of RA induced significantly higher p63 (+) cells compared to other 
concentrations of RA in the ACC system (Figure 9).  Additionally, unlike findings of  
Metallo et al.I found that continuous application of 0.5µM of RA for up to day 20 of 
culture resulted in higher expression of p63. Moreover, I also found a significant 
increase in the expression of neural markers (pax6 and sox1) (Figure 10). A possible 
explanation for the high neural contamination could be due to the expression of FGFs 
by fibroblasts which induce neural differentiation of hESCs through the ERK1/2-
PARP-1 pathway (Yoo et al.2011).  Therefore it was essential to inhibit the neural 
differentiation so as to improve the keratinocyte differentiation from hESCs and to 
increase the purity of the keratinocyte population. 
 
4.1.1.3 Activin inhibits neural pathway while inducing keratinocyte 
differentiation in ACC system 
  
The results discussed above led us to focus on neural inhibition. Previously BMP4 
has been used to inhibit the neural differentiation, but was not found to be  very 
effective (Wilson et al.1997 ; Harland 2000 ; Wilson et al.2001 ; Metallo et al.2008).   
Therefore, in this phase of the study I postulate that Activin, which is a member of 
the TGFβ family, may be a potent inhibitor of neural pathways. Previously, Activin 
has been used to maintain the mouse embryonic stem cells and hESCs at their 
pluripotency (James et al.2005 ; Vallier et al.2005 ; Beattie et al.2005)  by inhibition 
of default neural differentiation pathway  (Camus et al.2006 ; Patani et al.2009). 
However, the effect of Activin A on keratinocyte differentiation in the presence of 
RA has never been reported. Therefore, it is of my interest to find the effect of dose 
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modulation and temporal application of Activin on inhibition of neural differentiation 
alone, without effecting keratinocyte induction. The application of 25ng/ml Activin at 
day 9 for the period of 3 days (from day 9 to day 11) was found to be the most 
effective (Figure 11;Figure 12) and resulted in expression of 85% ± 4.5(SEM) of p63 
(+) cells from hESCs at day 20 when in the ACC system (Figure 14).  However, the 
molecular mechanism of the downstream signalling pathway for the abovementioned 
effect requires further investigation.  
 
4.1.1.4 Characterization of hESCs-Kert differentiated in ACC system 
 
 
After optimization of in vitro condition, hESCs were differentiated into keratinocytes 
in the ACC system. hESCs-Kert
ACC 
were characterized at different points in time 
(Figure 15). I observed that in vitro hESCs-Kert differentiation from hESCs followed 
the same hierarchy of embryonic keratinocyte differentiation. During embryogenesis 
the K18 (+) cells in primitive epithelium are replaced by p63 (+) cells. Subsequently, 
these progenitor cells give rise to basal keratinocytes (K14 (+) and integrin alpha 6(+) 
cells) cells of stratified epidermis (Shalom-Feuerstein et al.2011). Addition of Activin 
was able to inhibit neural differentiation, while permitting keratinocyte 
differentiation. By the end of day 30 of differentiation, hESCs-Kert
ACC 
expressed 
keratinocyte markers at mRNA (K14, K18, p63) and protein levels (K14 and α 
integrin) (Figure 15; Figure 16) Moreover, hESCs-Kert
ACC 
were able to undergo 
terminal differentiation to epidermal differentiating keratinocytes in DSFM 
supplemented with 1.5 mmol/L of calcium chloride(Figure 16d). 
Similar to Guenou et al findings, hESCs-Kert
ACC 
were able to maintain a high 
percentage of K14(+) cells in serum-free medium (Figure 17a) and were able to 
propagate for 10 passages without reaching the Hayflick limit (Figure 17b), these 
results were further confirmed by measurement of telomere length and Telomerase 
Reverse Transcriptase (TERT) expression (Figure 17c; Figure 17d).  
Recently, Guenou et al co-cultured hESCs with mouse NIH 3T3 fibroblast cells for 
the induction of keratinocyte differentiation and were able to get 50-55 % of K14(+) 
cells in 40 days (which subsequently required sorting to achieve approximately 96% 
of K14(+) cells). On the other hand, through my differentiation protocol in the ACC 
system, I were able to get 78% ± 7.5 (SE) of K14 (+) cells by day 30 and > 95% of 
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K14 (+) cells on subsequent culture. My protocol does not require cell sorting to get 
the same percentage of K14 (+) cells as previously reported (Guenou et al.2009). 
 





4.1.2.1 Application of Activin results in BM like ECM extraction from 
hESCs-ebF 
 
For a better clinical relevance, I established an improved defined, serum and feeder-
free AFF system by extracting BM like ECM from hESCs-ebF. ECM from the BM, 
which is also referred to as Type IV matrix, mainly consists of Collagen Type IV, 
Laminin and Proteoglycan. BM plays an important role in keratinocyte differentiation 
(Miner et al.1997; Fleischmajer et al.2000)  proliferation and migration (Pouliot et 
al.2002).Collagen Type IV is secreted predominantly by keratinocytes. However, it 
has previously been shown that TGF-β induces fibroblasts to secrete Collagen IV 
(Lam et al.2004). Additionally, TGF-β was found to up-regulate procollagen 
expression (cytoplasmic collagen) by fibroblasts (Lam et al. 2004). Subsequently, 
procollagen undergoes hydroxylation and glycosylation (post-translational 
modification) to form a triple helix and is extruded from the cells (Tuan et al. 1998 ; 
Niessen et al.1999 ; Derynck et al.2003 ; Mukhopadhyay et al. 2007). TGF-β and 
Activin share the same SMAD pathway. 
I was unable to extract ECM containing Collagen Type IV from hESCs-ebF in the 
presence of crowding medium without Activin (Figure 19a). Therefore, I 
hypothesized that addition of Activin in a crowding medium may cause the 
expression and extraction of Collagen IV in hESCs-ebF derived ECM. I found that 
application of Activin not only resulted in expression of Collagen Type IV in ECM 
substrate (Figure 19b) but also enhanced the overall extraction of ECM from hESCs-
ebF (Figure 20b).  
 
4.1.2.2 Characterization of AFF system  and hESCs-KertAFF 
 
Keratinocyte differentiation in the AFF system (hESCs-Kert
AFF
) followed the same 
hierarchy of keratinocyte marker expression as hESCs-Kert
ACC
 (Figure 21 and Figure 
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22). In addition, I found relatively pure population of hESCs-Kert
AFF
  as compared to 
hESCs-Kert
ACC
 on day 30 from the day of differentiation (Figure 23). The possible 
explanation of getting better efficiency in terms of purity through AFF system could 
be enhanced migration of peripheral cells from hESC colonies which then expressed 
the initial keratinocyte markers for differentiation. These differentiated peripheral 
cells migrate and give rise to new colonies of differentiated cells. In contrast to 
feeder-free system, feeder cells in the co-culture system are likely to limit the 
movement of differentiated peripheral cells, thus resulting in need of longer chemical 
exposure in the co-culture system for the induction of hESCs into keratinocyte 
lineage.  
Recently, Metallo et al. used the xenogeneic feeder-free system (Matrigel) for 6-10 
days in a differentiation medium and then sub cultured on gelatin-coated plates to get 
approximately 87% K14(+) cells from hESCs by day 30. However, I induced 
differentiation of hESCs on the AFF system and sub cultured on human Collagen 
Type IV to obtain similar results.  
 
4.1.3 Conclusion of Phase 1  
 
Although I were able to differentiate hESCs into keratinocytes with the minimum use 
of materials from animal sources, DSFM and the medium used to derive hESCs-ebF 
and ECM were not totally free from animal components. Nevertheless, in my study I 
have demonstrated that successful differentiation of expandable and highly-enriched 
populations of keratinocytes is possible without using xenogeneic feeders or ECM. I 
also described the pivotal role of Activin in keratinocyte differentiation and in 
production of specific types of ECM from fibroblast. Therefore, protocols described 
in this study are yet another step in bringing stem cell-based therapies closer to the 
clinics. 
This work has been accepted and published in Journal of Investigative 
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4.2 Phase 2: hESCs-Kert as an alternative research model for the 
study of immune response 
 
In this phase of my study I demonstrated hESCs-Kert as an alternative, reliable and 
consistent research model which showed almost similar immune response to P. 
gingivalis as immortalized keratinocyte cell lines (control research model). I used 
HaCaT as a control research model for the study of immunity as previously reported 
(Olaru et al. 2010).  Previously, my lab has reported the successful differentiation and 
detailed characterization of hESCs-Kert (Kidwai et al. 2012).Therefore, in this phase 




4.2.1 hESCs-Kert and HaCaT cell line share the similar kinetics of TLRs and 
cytokines  in the presence and/or absence of P. gingivalis   
 
TLRs play an important role in innate immunity (Akira et al. 2001). For more 
understanding of hESCs-Kert expression of different cytokines and TLRs under 
normal culture milieu, I first analysed the mRNA expression of TLR-2, TLR-4, TLR-
5, TLR-9, IL-6, IL-8, and TNF -α and iNOS by RT-PCR (Figure 26). To the best of 
my knowledge, the analyses of TLRs and cytokine expression in hESCs-derived 
keratinocytes has not been reported previously. However, previous studies have 
shown human keratinocytes expressed TLRs 1-10 under physiological conditions in 
vitro condition (Kawai et al. 2002 ; Mempel et al. 2003 ; Song et al. 2002 ; Baker et 
al. 2003). Moreover, the expression of different TLRs upregulates specific ligands to 
mount differential innate immune responses (Lebre et al. 2007). Furthermore, the 
detailed literature review shows that TLR-1 or TLR-6 form a heterodimer with TLR-
2 to recognize bacterial- and mycoplasma-derived lipoproteins respectively 
(Brightbill et al.1999; Takeuchi et al.2000). Additionally, TLR-2 identifies the 
infectious agents expressing pathogen-associated molecular patterns (PAMPs), gram 
positive bacteria, yeast and lipopolysaccharide (LPS) of Gram negative bacteria (P. 
gingivalis) (Hirschfeld et al.2001 ; Mempel et al.2003 ; Pulendran et al.2001 ; 
Yoshimura et al.2002). Viral double-stranded RNA is the ligand for TLR-3 
(Alexopoulou et al.2001). TLR-4 recognizes LPS and Protein A (Tapping et al. 2000)   
and TLR-5 identifies bacterial flagellin (Hayashi et al/ 2001). TLR-9 is the 
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responsible ligand for unmethylated  CpG motifs in bacterial DNA (Hemmi et 
al.2000). Therefore, based on these reviews, I used heat killed P. gingivalis, a 
common non-motile, gram negative bacteria, containing LPS as a major component 
in its cell wall (Naito et al.2008) to analyse the response of hESCs derived research 
model.  P. gingivalis resides in dental plaque present proximal to sulcular gingival 
keratinocytes and up-regulates the pro-inflammatory cytokines which contribute to 
inflammation in periodontitis (Giacaman et al.2009). 
hESCs-Kert and control HaCaT cell line were exposed to P. gingivalis for 72 hours 
and the kinetics of expression of TLRs receptors and cytokines were analysed at 
different time points (Figure 27). I found that apart from mimicking the control 
HaCaT cell line, the hESCs-Kert cells also behaved predictably the same way as 
control cell lines when exposed to heat-killed P. gingivalis. Previously, it has been 
shown that LPS of P. gingivalis stimulates TLR-2 (Hirschfeld et al.2001; Martin et 
al.2003; Pulendran et al.2001; Yoshimura et al.2002). Moreover, it is well-
established that the downstream signalling cascade of TLR-2 results in higher 
expression of IL-6, IL-8, and TNF-α and iNOS genes (Pivarcsi et al.2003; Park et 
al.2004; Faria et al.2012). Similarly, I found that the expression of TLR-2 was found 
to increase progressively in hESCs-Kert when challenged with P. gingivalis. 
Additionally, in agreement with the previous mentioned studies, I observed 
progressive up-regulation of IL-6 and IL-8 expression at mRNA level in hESCs-
derived research model. Additionally, it has been reported that up-regulation of IL-6 
and IL-8 is independent of TLR-4 expression (Mempel et al.2003 ; Hirschfeld et 
al.2001 ; Frost et al.2006). My results support this notion, as I found that the initial 
up-regulation (till 24 hours of P. gingivalis exposure) was followed by down-
regulation of TLR-4 after 24 hours of P. gingivitis exposure without effecting IL-6 
and IL-8 expression. Therefore, it is likely that the up-regulation of IL-6 and IL-8 
expression is caused by TLR-2 stimulation. Another possible explanation for the 
down-regulation of TLR-4 with the prolonged exposure time of P. gingivalis could be 
different LPS structures of P. gingivalis as compared to LPS from other gram 
negative bacteria E. coli (Hirschfeld et al.2001). Additionally, it has been shown that 
unlike LPS from other gram negative bacteria, LPS from P. gingivalis reduces the 
TLR-4 expression by the activation of IRAK-M, SOCS-1 and MyD88 as previously 
described (Coats et al.2002 ; Coats et al.2003).Although there was an initial 
upregulation of TLR-4 expression in control HaCaT cell line and hESCs-Kert at 
mRNA level, this is likely caused by the Lipid A present in LPS of P. gingivalis 
(Darveau et al.2004). Moreover, this could be due to the use of whole bacteria instead 
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of any purified component in my study; as during the infection host would be 
exposed to multiple components of the cell wall rather than purified component. 
Therefore, I cannot rule out the possibility of initial up-regulation of TLR-4 by other 
components of P. gingivalis (Pivarcsi et al.2003; Seo et al.2002; Darveau et al.2004; 
Hashimoto et al.2004). 
In addition, I observed an up-regulation of TNF-α gene expression in hESCs-Kert 
which is supportive of Li et al’s   findings, which have shown the up-regulation of 
pro-inflammatory cytokine TNF-α in keratinocytes by P. gingivalis (Li et 
al.2005).The possible mechanism of TNF-α stimulation could be via   Membrane-
bound mucin 1 (MUC1) dependent pathway which is responsible for attachment of 
bacteria to host cells as previously described (Li et al.2003). Hence, at this point of 
study, my hESCs-derived model showed similar response as control research model.   
 
Beside vast similarities of hESCs-Kert and control cell line, I found some disparate 
immune responses by hESCs-Kert and control HaCaT which need to be discussed. 
Interestingly, I did not find any significant up-regulation in iNOS in control HaCaT 
cell line at mRNA level. However, my hESCs-Kert showed the progressive increase 
in iNOS expression at mRNA level with the increased exposure time of P. gingivalis. 
Up-regulation of iNOS expression in hESCs-Kert supports previous studies which 
have shown the similar response in human keratinocyte in the presence of P. 
gingivalis (Mempel et al.2003; Pivarcsi et al.2003). These results support my hESCs-
Kert as a reliable research model.  
 
4.2.2 TLRs-2 activation results in downstream NF-κB activation in hESCs-
Kert and HaCaT in the presence or absence of P. gingivalis 
 
TLRs signalling ends in the activation of pathways like proapoptotic caspase 
signalling, JNK/AP-1 and NF-κB pathways (Muzio et al.1998; Aliprantis et al.1999; 
Aliprantis et al.2000; Medzhitov et al.1997). NF-κB transcription factor belongs to 
Rel family, and plays a vital role in regulating the expression of many genes involved 
in inflammatory, immune, and apoptotic processes (Zhang et al.2001; Silverman et 
al.2001).  In keratinocytes, TLR-MyD88-NF-kB pathway plays an important role in 
innate immunity (Mempel et al.2003; Song et al.2002; Pivarcsi et al.2003).  
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Additionally, Lee Y et al in 2010 nicely showed the TLR-2 association with NF-κB 
in keratinocytes (Lee et al.2010). My findings support the previous results and I 
found the expression of NF-κB to follow the same kinetics as TLR-2 without 
effecting TLR-4 expression (Figure 28). However this conclusion requires further 
investigation.  
4.2.3 Conclusion of Phase 2 
 
Although I proposed the new research tool from hESCs, further investigations need to 
be done for the validation of my findings. Overall, my results support the potential 
application of hESCs as an unlimited cell source for standardized derivation of 
keratinocytes which can be used as an alternative, consistent and reliable research 
tool with no inter-donor variability. Additionally, the similarities between my study 
and previous reports further support the eligibility of the hESCs-Kert as a reliable 
keratinocyte research model. 
This work has been accepted in Journal of Oral Pathology and Medicine in 2013. 
 
4.3 Phase 3: hESCs derived multilayer epithelium: permeability 
testing model for industrial application 
 
In this phase of my study, I addressed a possible industrial application of hESCs-Kert. 
I constructed the keratinized multilayer epithelium tissue from hESCs-Kert and did 
the permeability testing. In vitro permeability assay benefits in identifying the 
changes in permeability can be followed over time after challenging the tissue with 
bioactive compounds and toxins and having the structural changes associated with 
these agents assessed. The tissue covering the surface of the skin and the lining of the 
oral cavity represents the primary barrier between the external environment and the 
deeper tissues.  As David Norris in 1989 has reported the role of superantigens in 
epidermal disease; “Without penetration there is no access, and without access, there 
is nothing” (Norris et al.1989). Therefore, a realistic and reproducible model for 
studying barrier properties of the protective surface of skin and oral mucosa will 
represent an important tool for preclinical testing and for facilitating the translation of 
therapeutic compounds into clinical use.  
 





4.3.1 Characterization of hESCs-MLE at morphological, mRNA and protein 
level 
 
To achieve my aim, I made a step-wise strategy in which each step was built on the 
outcomes of the preceding step: In the first step, I contructed MLE from hESCs 
(Figure 29 and Figure 30). In the second step I characterized the MLE at 
morphological, mRNA and protein level (Figure 29; Figure 30; Figure 31; Figure 32; 
Figure 33; Figure 34; Figure 35). In the third step, I characterized the MLE in terms 
of its permeability (Figure 36; Figure 37; Figure 38). Similar to Guenou et al 
findings, my hESCs-Kert were able to construct MLE in 14 days at air-liquid 
interface.  Furthermore, the stratification of cells in hESCs-MLE was found to be 
similar as the control (Figure 30). Additionally, it has been previously reported that 
stratification of keratinocytes in in vitro constructed MLE was not found to be similar 
to the in vivo constructed MLE in which stratified squamous tissue consist of cells 
closely attached to each other in a number of distinct layers (basal, prickle cell, 
granular and keratinized layers) (Guenou et al.2009; Hewitt et al.2009 ; Metallo et 
al.2010). My findings were in support of previously discussed studies (Guenou et 
al.2009 ; Hewitt et al.2009 ; Metallo et al.2010) and I found that hESCs-MLE consist 
of 4-5 layers terminally differentiated keratinocytes with the  cornified layer on the 
top. For potential industrial application, the keratinized layer was of my interest as the 
epithelial surface of the skin and of the masticatory regions of the oral mucosa i.e. 
hard palate and gingiva;  is inflexible, tough, and resistant to abrasion as a result of 
the formation of a surface layer of keratin. Moreover, it also represents the primary 
barrier to the penetration of exogenous material and microbes and their toxins.    
The mechanical barrier properties depend both on the intracellular filaments known 
as cytokeratins and the cohesion between cells provided by modifications of the 
adjacent membranes of cells, the most common of which is the desmosome (Presland 
& Dale 2000). Cytokeratin proteins K5, K6, K14, K16, and K17 are constitutively 
produced by cells of all terminally differentiated keratinocytes of squamous epithelia 
in culture. Moreover, K1, K10, K13, K19, Involucrin and Filaggrin production is 
useful as specific markers for assessing differentiation of epithelial cells (Lillie et 
al.1988) My findings are in support of Lillie et al. findings and hESCs-MLE was 
found to express important cytokeratins specific to terminally differentiated 
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keratinocytes at mRNA level. Furthermore, I analysed the expression of Filaggrin and 
Involucrin at protein level by western blot in hESCs-MLE and it is well-established 
that Involucrin and Filaggrin are the most useful cytokeratin markers in terminally 
differentiated MLE. Gibbs et al. in 2000 have reported that keratinocytes in the 
superficial part of the MLE develop a marked thickening on the inner (intracellular) 
aspect of cell membrane so as to form a cornified envelope that contributes to the 
considerable resistance of the keratinized layer to mechanical and chemical insult 
(Gibbs & Ponec 2000). Moreover, previously, it has been shown that Involucrin and 
Filaggrin are the major constituents of the cornified envelope (Presland et al.2000 ; 
Gibbs et al.2000)  Furthermore, in superficial layer,  Filaggrin and Involucrin are 
found to be associated with keratohylin granules which are thought to facilitate the 
aggregation and formation of cross-links between the cytokeratin filaments which 
results in the formation of keratinized superficial layer  (Antsiferova et al.2009 ; 
Henry et al.2011).  Therefore, it is of my interest to analyse the expression of 
Filaggrin and Involucrin in hESCs-MLE at protein level for permeability testing. My 
findings were in support of Antsiferova et al and Henry et al’s findings and hESCs-
MLE was able to express Filaggrin and Involucrin at mRNA (Figure 31) and protein 
levels (Figure 32; Figure 34).  
 
4.3.2 hESCs-MLE as a novel model for Permeability Assay 
 
Permeability barrier properties rely on the upper part of the prickle cell layer which 
appears an  organelle called the membrane-coating or lamellate granule that  probably 
originates from the Golgi system and contains a series of parallel lamellae consisting 
of lipids and glycolipids. At the boundary between the cornified and granular layers, 
the lipid lamellae are extruded into the extracellular spaces by the fusion of   
membrane-coating granules with the cell plasma membrane (Landmann 1988). Here 
it undergoes enzymatic processing to produce a lipid mixture consisting of ceramides, 
cholesterol and fatty acids. This intercellular lipid is uniquely organized into a multi 
lamellar complex that fills most of the intercellular space of the STC. Therefore, the 
barrier properties of STC depend on the phase behaviour of the intercellular lipids. 
Moreover, epidermis and all of the oral epithelia produce substantial quantities of 
glycosylceramides but differ in the amount of deglycosylation in the formation of 
their barriers (Squier et al. 1997). Furthermore, in superficial layers of epidermis, 
where the barrier is highest, consist of more than 98% of the ceramide (Law et 
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al.1995).  However, nine subclasses of ceramides have been identified in 
mammalians. Moreover, CER1, CER4, and CER9 are unique to human STC and the 
other types are found in other mammalians like pig and monkey’s STC which makes 
their permeability barrier properties different (Squier et al. 1997). Therefore, MLE of 
animal origin cannot be considered as an authentic counterpart of human MLE 
(Balimane et al.2006).Thus, my hESCs-MLE provides an alternative MLE model 
which is human by origin, thus providing a better human relevance Moreover, it is 
important to analyse the permeability barrier properties of hESCs-MLE for potential 
industrial application.  
For permeability testing; I used tritiated water. Tritiated water is one of the most 
commonly used probes for monitoring epithelial permeability (Squier et al.1997). It is 
chemically inert and a sensitive indicator of changes in barrier functions because of 
its relatively high tissue permeability. Previously, tritiated water with specific activity 
of 1µCi/ml has been used for numerous studies of epithelial permeability including 
skin, oral mucosa (Lesch et al.1989)  and vagina  (van der Bijl et al.1998 ; van der 
Bijl et al.1998). Other research groups have also used High molecular weight dextran 
20kDa, bioactive peptides such as TGF-β (Squier et al. 2008), cytokines (Brosnahan 
et al.2008), toxins such as hemolysins (Squier et al.2008),  and inactivated HIV that 
that can be obtained commercially labelled for therapeutic and pathological studies.  
I found hESCs-MLE showing the similar trend of permeability (Flow flux and Kp) 
compared to control. Interestingly, I found that MLE with dermal compartment 
showed slightly more resistance than MLE without dermal compartment. The 
possible reason for this result could be due to the construction of more homogenous 
and more organized MLE in the presence of fibroblast compared to MLE without 
dermal compartment.  My finding is in support of previous studies (Liu et al.2011 ; 
Metcalfe et al.2007) which have shown that dermal compartment play an important 
role in MLE formation. Moreover, it is plausible that MLE with dermal compartment 
would mimic the tissue explant more closely with thin layer of dermal tissue attached 
the same way as in the tissue biopsies taken from patient donors. My results 
demonstrated that hESCs-ebF were not able to show any permeability, however it 
seems that they play an important indirect role in keratinization of MLE which 
resulted in an increase in permeability of MLE. 
 
 




4.3.3 Conclusion of Phase 3  
Ideal MLE models play an important role in the success of new therapeutic modalities 
and understanding of disease pathogenesis and evaluating new drug delivery system. 
It is evident from my findings that while human tissue provides the most realistic 
method for studying human tissue function, hESCs-MLE can overcome numerous 
problems involving ethical procurement, inter-donor variability and risk of infection. 
Furthermore, the differences between the skin and oral mucosa of human and most 
small laboratory animal models make current models unsuitable for realistic studies 
of structure and function. Furthermore, the larger experimental animals raise 
problems of availability, cost and disease transmission. Therefore, investment to 
establish such an ideal MLE model estimated $100 million per annum in US. Europe 
shows approximately the same trend. Thus, organotypic culture models offer many 
benefits for characterizing barrier function and facilitating studies on drug delivery, 
infection and pathogenesis. hESCs-derived MLE offers the possibility of abundant 
tissue that is structurally and functionally relevant and consistent.  
This work has won ‘NUS Entrepreneur Award’ to file a patent application.
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5 Future Perspective   
 
5.1 Phase 1:  hESCs differentiation into clinically compliant 
hESCs-Kert   
 
My future perspectives for this phase are as followed 
a) Ivivo model to analyse the potential of hESCs-Kert to be used as epidermal 
grafts.  
b)  Human MHC expression need to measure in hESCs-Kert and need to 
compare with primary allogeneic keratinocytes. Furthermore, studies need be done to 
confirm this in in vivo model. Moreover, further down-regulation of MHC expression 
of hESCs-Kert can be done to enhance the clinical application of hESCs-Kert.   
c) The immune modulatory effect of fibroblast is well established. Therefore, 
hESCs-ebF in conjunction with hESCs-Kert needs to implant in in vivo models and 
immune modulatory effect of hESCs-ebF on hESCs-Kert need to be analysed.  
5.2 Phase 2: hESCs-Kert as an alternative research model for the 
study of immune response  
 
In this phase of the study, following are the future directions which can be taken 
a) hESCs-Kert can be used as alternative model for the study of ageing. Current 
models are hampered by limited availability and batch to batch variation.  Unlimited 
supply of hESCs-Kert, which are human in origin can offered as an authentic research 




5.3 Phase 3: hESCs-MLE: permeability testing model for 
industrial application 
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MLE as an industrial research model is in use for last few decades. In this study, I 
tested the permeability of hESCs-MLE but following are the studies which can be 
conducted in future 
a) hESCs-MLE can be used to study the mechanism of penetration of pathogens 
i.e. Human papillomaviruses (HPVs). HPVs are DNA viruses which are specialized 
for replication in external epithelia which limits their scope to skin and mucosal 
surfaces. However, mechanism of their penetration across the superficial permeability 
barrier and their pathogenesis in skin infections are poorly understood due to the lack 
of available research models. Therefore, the development of an in vitro model that 
can reproduce the appropriate mechanical and permeability characteristics of the 
normal tissue is critical to the studies of pathogenesis of HPVs. 
b) hESCs-MLE can be used to test pharmaceutical products for pre-clinic 
studies. Such models are in great demands in Europe and North America. hESCs-
MLE as an industrial model not only shorten the time phase require but also reduces 
the cost require for the development of pharmaceutical products.
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6 Limitations  
 
6.1 Phase 1:  hESCs differentiation into clinically compliant 
hESCs-Kert   
 
a) I used keratinocyte defined serum free medium (DSFM) to cultured hESCs-
Kert. DSFM is not completely xeno protein free.  
b) hESCs-KertAFF were able to grow for 7 passages. Further optimization of 
culture system need to be done to obtain longer passages of hESCs-Kert 
AFF
. 
c) No in vivo study was done 
 
6.2 Phase 2: hESCs-Kert as an alternative research model for the 
study of immune response  
a) I used single strain of bacteria which does not mimic the real clinical 
condition. Wider range of microorganism need to be used to verify the 
immune response of hESCs-Kert 
 
6.3 Phase 3: hESCs-MLE: permeability testing model for 
industrial application 
a) I used organotypic culture made up of immortalized keratinocyte (HaCaT). 
However, it is not considered as best control for permeability studies. 
Therefore, human skin or organotypic culture made up of human primary 
keratinocyte would be more appropriate. 
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